Advertisement

C

  • Günter Seyffart
Chapter

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1522, caffeine.Google Scholar

Main references

  1. Bordier PJ, Marie PJ, Arnaud CD: Evolution of renal osteodystrophy: Correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Kidney Int 7 (Suppl 2):102, 1975Google Scholar
  2. Boris A: Structure-activity relationships of vitamin D analogues. Am J Med 62:543, 1977PubMedCrossRefGoogle Scholar
  3. Brancaccio D, Graziani G, Galmozzi C, Ponticelli C: 25-Hydroxy-vitamin-D deficiency and osteomalacia of chronic renal failure. Lancet I:199, 1977CrossRefGoogle Scholar
  4. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes and F Murad.Google Scholar
  5. Hahn TJ, Biage SJ, Scharp CR, Avioli LV: Phenobarbital-induced alterations in vitamin D metabolism, J Clin Invest 51:741, 1972PubMedCrossRefGoogle Scholar
  6. Hahn TJ, Hendin BA, Scharp CR, Haddad JG jr: Effects of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287:900, 1972PubMedCrossRefGoogle Scholar
  7. Henning HV, Fuchs C: Renale Osteopathie. Nieren- und Hoch-druckkrankh 13:235, 1984Google Scholar
  8. Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986PubMedCrossRefGoogle Scholar
  9. Rutherford WE, Blondin J, Hruska K, Kopelman R, Klahr S, Slatopolsky E: Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease. Kidney Int 8:320, 1975PubMedCrossRefGoogle Scholar
  10. Silver J, Shvil Y, Fainaru M: Vitamin D transport in an infant with vitamin D toxicity. Br Med J 2:93, 1978PubMedCrossRefGoogle Scholar
  11. Teitelbaum SL, Bone JM, Stein PM, Gilden JJ, Bates M, Boisseau VC, Avioli LV: Calcifediol in chronic renal insufficiency. Skeletal response. JAMA 235:164, 1976PubMedCrossRefGoogle Scholar

Main references

  1. Baker RLI, Muir JW, Sharman VL, et al.: Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26:185, 1986PubMedGoogle Scholar
  2. Boris A: Structure-activity relationships of vitamin D analogues. Am J Med 62:543, 1977PubMedCrossRefGoogle Scholar
  3. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368, 1988PubMedCrossRefGoogle Scholar
  4. Feinfeld DA, Sherwood LM: Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int 33:1049, 1988PubMedCrossRefGoogle Scholar
  5. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes and F MuradGoogle Scholar
  6. Habener JF, Mahaffey JE: Osteomalacia and disorders of vitamin D metabolism. Annu Rev Med 29:327, 1978PubMedCrossRefGoogle Scholar
  7. Henning HV, Fuchs C: Renale Osteopathie. Nieren-und Hoch-druckkrankh 13:235, 1984Google Scholar
  8. Jubiz W, Haussler MR, McCain TA, Tolman KG: Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 44:617, 1977PubMedCrossRefGoogle Scholar
  9. Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986PubMedCrossRefGoogle Scholar
  10. Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW: Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med 105:239, 1985PubMedGoogle Scholar
  11. Mawer EB, Backhouse J, Davies M, Hill LF, Taylor CM: Metabolic fate of administered 1,25-dihydroxycholecalciferol in controls and in patients with hypoparathyroidism. Lancet I:1203, 1976CrossRefGoogle Scholar
  12. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2134, 1984CrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1079, calcium carbonateGoogle Scholar
  2. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157, 1986PubMedCrossRefGoogle Scholar

Main reference

  1. Benakis A, Glasson B, Bouvier CA, Ritschard J, Krahenbuhl B, Jung A, Hachen HJ: Metabolisme et pharmacocinetique du dobesilate de calcium chez l’homme. Thérapie (Paris) 29:211, 1974Google Scholar

Main reference

  1. Nixon PF, Bertino JR: Effective absorption and utilization of oral formyltetrahydrofolate in man. N Eng J Med 286:175, 1972CrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1030, calcium glycerinophosphateGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:837, calcium trisodium penetateGoogle Scholar

Main references

  1. Ginn HE, Anderson KE, Mercier RK, Stevens TW, Matter BJ: Camphor intoxication treated by lipid dialysis. JAMA 203:230, 1968PubMedCrossRefGoogle Scholar
  2. Jacobziner H, Raybin HW: Camphor poisoning. Arch Pediatr 79:28, 1962PubMedGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1552, camphorGoogle Scholar

Main references

  1. Brogden RN, Todd PA, Sorkin EM: Captopril — an uptdate of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 36:540, 1988PubMedCrossRefGoogle Scholar
  2. Campbell BC, Shepherd AN, Elliot HL, McLean K, Reid JL: Prolonged converting enzyme inhibition following captopril in patients with renal insufficiency. Br J Clin Pharmacol 12:755, 1982CrossRefGoogle Scholar
  3. Case DB, Atlas SA, Mouradian JA, Fishman RA, Sherman RL, Laragh JH: Proteinuria during long-term captopril therapy. JAMA 244:346, 1980PubMedCrossRefGoogle Scholar
  4. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN: Captopril kinetics. Clin Pharmacol Ther 31:452, 1982PubMedCrossRefGoogle Scholar
  5. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ: Elimination kinetics of captopril in patients with renal failure. Kidney Int 25:942, 1984PubMedCrossRefGoogle Scholar
  6. Hays R, Aquino A, Lee BB, Lo R, Currier CB jr: Captopril-induced acute renal failure in a kidney transplant recipient. Clin Nephrol 19:320, 1983PubMedGoogle Scholar
  7. Heel RC, Brogden RN, Speight TM, Avery GS: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20:409, 1980PubMedCrossRefGoogle Scholar
  8. Hirakata H, Onoyama K, Iseki K, Omae T, Fujimi S, Kawahara Y: Captopril (SO 14225) clearance during hemodialysis treatment. Clin Nephrol 16:321, 1981PubMedGoogle Scholar
  9. Hoorntje SJ, Kallenberg CG, Weening JJ et al.: Immune-complex glomerulopathy in patients treated with captopril. Lancet I:1212, 1980CrossRefGoogle Scholar
  10. Johnston CI: Handbook of hypertension vol. 5. Amsterdam, New York: Elsevier Science Publishers, 1984 p 272Google Scholar
  11. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:468, captoprilGoogle Scholar
  12. Pessina AC, Semplicini A, Rossi G et al.: Effects of captopril on renal function in hypertensive patients. Am J Cardiol 49:1572, 1980CrossRefGoogle Scholar
  13. Ram CVS: Captopril. Arch Intern Med 142:914, 1982PubMedCrossRefGoogle Scholar
  14. Report from the Captopril Collaborative Study Group: Does Captopril cause renal damage in hypertensive patients? Lancet I:988, 1982Google Scholar
  15. Rommel AJ, Pierides AM, Heald A: Captopril elimination in chronic renal failure. Clin Pharmacol Ther 27:282, 1980Google Scholar
  16. Sturgill BC, Shearlock KT: Membranous glomerulopathy and nephrotic syndrome after captopril therapy. JAMA 250:2343, 1983PubMedCrossRefGoogle Scholar
  17. Textor SC, Bravo E, Fouad FM et al.: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73:719, 1982PubMedCrossRefGoogle Scholar
  18. Vidt DG, Bravo EL, Fouad FM: Captopril. N Engl J Med 306:214, 1982PubMedCrossRefGoogle Scholar
  19. Warren SE, O’Connor DT: Hyperkalemia resulting from captopril administration. JAMA 244:2551, 1980PubMedCrossRefGoogle Scholar
  20. Yeung JHK, Breckenridge AM, Park BK: Drug-protein conjugates. IV. The effect of acute renal failure on the disposition of (14C) captopril in the rat. Biochem Pharmacol 32:2467, 1983PubMedCrossRefGoogle Scholar

Main reference

  1. Johnson G, Regardh CG: Clinical pharmacokinetics of β-adrenoreceptor blocking drugs. Clin Pharmacokinet 1: 233, 1976CrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1329, carbacholGoogle Scholar

Main references

  1. Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A: Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27:83, 1980PubMedCrossRefGoogle Scholar
  2. Christian T, Dam M: Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 49:543, 1973CrossRefGoogle Scholar
  3. Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, Tyrer JH: The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol 12:451, 1977PubMedCrossRefGoogle Scholar
  4. Eichelbaum M, Kothe KW, Hoffman F, von Unruh GE: Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 26:366, 1979PubMedGoogle Scholar
  5. Ghio L, Galato R, Giani M, Edefonti A, Appiani A, Piceni-Sereni L, Romeo A, Viani F: Efficacy and pharmacokinetics of carbamazepine (CBZ) in a child during haemodialysis. Electroencephalogr Clin Neurophysiol 55:2P, 1983Google Scholar
  6. Gruska H, Beyer KH, Kubicki ST, Schneider H: Klinik, Toxikologie und Therapie einer schweren Carbamazepine-Vergiftung. Arch Toxicol 27:193, 1971CrossRefGoogle Scholar
  7. Hooper WD, Dubetz DK, Bochner F, Cotter LM, Smith GA, Eadie MJ, Tyrer JH: Plamsa protein binding of carbamazepine. Clin Pharmacol Ther 17:433, 1975PubMedGoogle Scholar
  8. Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ: Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. J Toxicol Clin Toxicol 17:429, 1980CrossRefGoogle Scholar
  9. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM: Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 17:657, 1975PubMedGoogle Scholar
  10. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:400, carbamazepineGoogle Scholar
  11. Nicholls DP, Yasin M: Acute renal failure from carbamazepine. Br Med J 4:490, 1977CrossRefGoogle Scholar
  12. Perucca E, Richens A: Water intoxication produced by carbamazepine and its reversal by phenytoin. Br J Clin Pharmacol 9:302P, 1980CrossRefGoogle Scholar
  13. Pitlick WH, Levy RH, Troupin AS, Green JRJ: Pharmacokinetic model to describe self induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 65:462, 1976PubMedCrossRefGoogle Scholar
  14. Rane A, Höjer B, Wilson JT: Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther 19:276, 1976PubMedGoogle Scholar
  15. Rawlins D, Collste P, Bertilsson L, Palmer L: Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol 8:91, 1975PubMedCrossRefGoogle Scholar
  16. Richens A, Warrington S: When should plasma drug levels be monitored? Drugs 17:488, 1979PubMedCrossRefGoogle Scholar
  17. Sillanpää M: Carbamazepine. Pharmacology and clinical use. Acta Neurol Scand 64 (Suppl 88):5, 1981Google Scholar
  18. Zarday Z, Soberman RJ: Carbamazepine in uremic neuropathy. Ann Intern Med 84:296, 1976PubMedGoogle Scholar

Main references

  1. Bacq ZM, Derouaux G: La semicarbazone de l’adrenochrome. Sêm Hôp Paris 26: 3347, 1950PubMedGoogle Scholar
  2. Fischer P, Lecomte J: Action des quinones et des produits d’oxydation de l’adrenalisme sur la coagulation sanguine. Intervention des groupes — SH. Arch Int Physiol 56: 223, 1949CrossRefGoogle Scholar

Main references

  1. Appel G: Acute interstitial nephritis associated with carbenicillin therapy. Arch Intern Med 138:1265, 1978PubMedCrossRefGoogle Scholar
  2. Bailey RR, Eastwood JB, Vaughan RB: The pharmacokinetics of an oral form of carbenicillin in patients with renal failure. Postgrad Med J 48:422, 1972PubMedCrossRefGoogle Scholar
  3. Cheigh JS: Drug administration in renal failure. Am J Med 62:555, 1977PubMedCrossRefGoogle Scholar
  4. Eastwood JB, Curtis JR: Carbenicillin administration in patients with severe renal failure. Br Med J 1:486, 1968PubMedCrossRefGoogle Scholar
  5. Hoffman TA, Cestero R, Bullock WE: Pharmacokinetics of carbenicillin in patients with hepatic and renal failure. J Infect Dis 122 (Suppl):S75, 1970CrossRefGoogle Scholar
  6. Johny M, Derrington AW, Lawrence JR: Carbenicillin therapy in renal failure. Med J Aust 2:681, 1969PubMedGoogle Scholar
  7. Klastersky J, Vanderkelen B, Daneau D, Mathieu M: Carbenicillin and hypokalemia. Ann Intern Med 78:744, 1973Google Scholar
  8. Latos DS, Bryan CS, Stone WJ: Carbenicillin therapy in patients with normal and impaired renal function. Clin Pharmacol Ther 17:692, 1975PubMedGoogle Scholar
  9. Lipner HI, Ruzany F, Dasgupta M et al.: The behavior of carbenicillin as a nonresorbable anion. J Lab Clin Med 86:183, 1975PubMedGoogle Scholar
  10. Lurie A, Ogilvie M, Townsend R, Gold C, Meyers AM, Goldberg B: Carbenicillin-induced coagulopathy. Lancet I:1114, 1970CrossRefGoogle Scholar
  11. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:139, carbenicillin disodiumGoogle Scholar
  12. Nakano H, Sasaki K, Mizoguchi M et al.: Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function. Chemotherapy 23:299, 1977PubMedCrossRefGoogle Scholar
  13. Pancoast SJ, Neu HC: Kinetics of mezlocillin and carbenicillin. Clin Pharmacol Ther 24:108, 1978PubMedGoogle Scholar
  14. Standiford HC, Jordan MC, Kirby WMM: Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis 122 (Suppl):S9, 1970CrossRefGoogle Scholar
  15. Tabernero-Romo JM, Corbacho L, Sanchez S et al.: Effects of carbenicillin on blood coagulation: A study in patients with chronic renal failure. Clin Nephrol 11:31, 1979PubMedGoogle Scholar
  16. Whelton A, Carter CG, Garth MA: Carbenicillin-induced acidosis and seizures. JAMA 218:1942, 1971PubMedCrossRefGoogle Scholar
  17. Whelton A, Carter CG, Bryant HH, Porteous LA, Walker WG: Carbenicillin concentrations in normal and diseased kidneys: A therapeutic consideration. Ann Intern Med 78:659, 1973PubMedGoogle Scholar
  18. Zwelling IA, Balow JE: Hypersthenuria in high-dose carbenicillin therapy. Ann Intern Med 89:225, 1978PubMedGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1080, carbonoxolone sodiumGoogle Scholar

Main references

  1. Johnson RD, Ruthven CR, Goodwin BL, Sandler M: In vivo assessment of decarboxylase inhibition or potentiation: Urinary dopamine and l-dopa output after l-dopa administration. J Neural Transm 38:181, 1976PubMedCrossRefGoogle Scholar
  2. Reid JL, Calne DB, Vakil SD, Allen JG, Davies CA: Plasma concentration of levodopa in parkinsonism before and after inhibition of peripheral decarboxylase. J Neurol Sci 17:45, 1972PubMedCrossRefGoogle Scholar
  3. Vickers S, Stuart EK, Bianchine JR et al.: Metabolism and carbidopa, an aromatic amino acid decarboxylase inhibitor in the rat, dog, rhesus monkey and man. Drug Metab Dispos 2:9, 1974PubMedGoogle Scholar

Main references

  1. Benker G, Reinwein D: Pharmacokinetics of antithyroid drugs. Klin Wochenschr 60:531, 1982PubMedCrossRefGoogle Scholar
  2. Jansson R, Lindström B, Dahlberg PA: Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 10:443, 1985PubMedCrossRefGoogle Scholar
  3. Kampmann JP, Hansen JM: Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 6:401, 1981PubMedCrossRefGoogle Scholar
  4. Melander A, Hallengren B, Rosendal-Helgesen S, Sjöberg AK, Wahlin-Boll E: Comparative in vitro effects and in vivo kinetics of antithyroid drugs. Eur J Clin Pharmacol 17:295, 1980PubMedCrossRefGoogle Scholar
  5. Skellern GG, Knight BI, Low CK, Alexander WD, McLarty DG, Kalk WJ: The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. Br J Clin Pharmacol 9:137, 1980PubMedCrossRefGoogle Scholar

Main references

  1. Beale HD, Rawling FFA, Figley KD: Clistin maleate. A clinical appraisal of a new antihistaminic. J Allergy 25:521, 1954PubMedCrossRefGoogle Scholar
  2. Cockrell JL: Acute hallucinogenic reaction to carbinoxamine maleate. J Toxicol Clin Toxicol 25:161, 1987PubMedCrossRefGoogle Scholar
  3. Garat BR, Landa CR, Rossi Richeri OF, Tracchia RO: Clinical, chemical, and pharmacologic relationships of antihistamines. A study of a new synthetic antihistaminic, carbinoxamine maleate (Clistin Maleate). J Allergy 27:57, 1956PubMedCrossRefGoogle Scholar

Main references

  1. Martin YC, Wiegand RG: Metabolism and excretion of chromonar and its metabolite in dog and man. J Pharm Sci 59:1313, 1970PubMedCrossRefGoogle Scholar
  2. Schraven E, Nitz RE, Klarwein M: Blutspiegel, Verteilung in den Organen und Ausscheidung von Carbochromen bei Ratte, Hund und Mensch. Arzneimittelforschung (Drug Res) 20:1905, 1970Google Scholar

Main references

  1. Alha AR: Debrominaton compounds of bromisoval and carbromal in poisoning. Ann Med Exp Fenn 41:95, 1963PubMedGoogle Scholar
  2. Butler TC: The metabolic fate of carbromal (2-bromo-2-ethyl-butyrylurea). J Pharmacol Exp Ther 143:23, 1964PubMedGoogle Scholar
  3. Drasch G, v. Meyer L, Engel J, Hauck G: Probleme des Zerfalls bromharnstoffhaltiger Tabletten. Dtsch Apotheker Ztg 118:1630, 1978Google Scholar
  4. Grabensee B, Hofmann K, Jax W, Königshausen T, Schnurr E, Schröder E: Klinik und Therapie der Bromcarbamid-Vergiftung. Dtsch Med Wochenschr 97:1911, 1972PubMedCrossRefGoogle Scholar
  5. Impens E: Über die physiologische Wirkung eines bromhaltigen Hypnotikums, des Adalins. Med Klin 6(II): 1861, 1910Google Scholar
  6. Merrill JP, Weller JM: Treatment of bromism with the artificial kidney. Ann Intern Med 37:186, 1952PubMedGoogle Scholar
  7. Schwabe U: Jährlich 1000 Todesfälle durch rezeptfreie bromcar-bamid-haltige Schlafmittel in der Bundesrepublik? Dtsch Med Wochenschr 102:885, 1977PubMedCrossRefGoogle Scholar
  8. Seyffart G: Antihistamines and other sedatives. F. Ethinamate and other sedatives. In: Haadad LM and Winchester JF (eds): Clinical management of poisoning and drug overdose. Philadelphia: Saunders, 1990, chapter 46, p. 850Google Scholar

Main references General

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:605, carmustineGoogle Scholar
  2. Ray JE, Wade DN, Graham GG. Day RO: Pharmacokinetics of carprofen in plasma and synovial fluid. J Clin Pharmacol 19:635, 1979PubMedGoogle Scholar
  3. Ray JE, Wade DN, Graham GG: Absorption and metabolism of (14C)carprofen in man. Clin Exp Pharmacol Physiol 6:175, 1979Google Scholar

Main references Renal damage

  1. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984PubMedCrossRefGoogle Scholar
  2. Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985PubMedCrossRefGoogle Scholar
  3. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984PubMedCrossRefGoogle Scholar
  4. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980PubMedCrossRefGoogle Scholar
  5. Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984PubMedCrossRefGoogle Scholar
  6. Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987PubMedCrossRefGoogle Scholar
  7. Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982Google Scholar
  8. Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986CrossRefGoogle Scholar
  9. Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984PubMedCrossRefGoogle Scholar
  10. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980PubMedCrossRefGoogle Scholar
  11. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980PubMedCrossRefGoogle Scholar
  12. Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982PubMedGoogle Scholar
  13. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986PubMedCrossRefGoogle Scholar
  14. Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxi-zität. Dtsch Med Wochenschr 110:469, 1985PubMedCrossRefGoogle Scholar

Main references

  1. Hasenfuß G, Schäfer-Korting M, Knauf H, Mutschler E, Just H: Pharmacokinetics of Carteolol in relation to renal function. Eur J Clin Pharmacol 29:461, 1985PubMedCrossRefGoogle Scholar
  2. Knauf H, Schäfer-Korting M, Mutschler E: Pharmakokinetik und biologiche Wirkdauer von β-Rezeptorenblockern bei Niereninsuffizienz. Internist 22:616, 1981PubMedGoogle Scholar
  3. Mori H, Kido M, Muralami N, Morita S, Kohri H, Nakagawa K: Metabolic fate of carteolol hydrochloride, 5-(3-tert-butyl-amino-2-hydroxy-propoxy)-3,4-dihydrocarbostyril hydrochloride, OPC-1085, a new β-blocker. V. Identification of metabolites in rat, dog and human. J Pharmaceut Soc Japan 97:350, 1977Google Scholar
  4. Morita S, linuma M, Kido M, Sakuragi S, Kohri H, Nishino H: Metabolic fate of carteolol hydrochloride (OPC-1085), a new β-adrenergic blocking agent. VIII. Pharmacokinetic studies of carteolol in man. Arzneimittelforschung (Drug Res) 27(II):2380, 1977Google Scholar
  5. Morita S, Irie Y, Sakuragi S, Kohri H, Nishino H: Metabolic fate of carteolol hydrochloride (OPC-1085), a new β-adrenergic blocking agent. VI. Pharmacokinetics of carteolol in rat, dog, rabbit and man. Folia Pharmacol Japon 73:299, 1977CrossRefGoogle Scholar

Main references

  1. Dominguez-Gil A, Castineiras MC, Tabernero JM, Rodriguiz Comenes JL, Castro S de: Pharmacokinetics of cephacetrile in patients with normal or impaired renal function. Eur J Clin Pharmacol 13:445, 1978CrossRefGoogle Scholar
  2. Dominguez-Gil A, Lanao JM, Tabernero JM, Rodriguiz Comenes JL, Castro S de: Pharmacokinetics of cephacetrile in patients undergoing hemodialysis. Eur J Clin Pharmacol 16:49, 1979PubMedCrossRefGoogle Scholar
  3. Spring P, Räber J, Reber H, Dettli L: Die Elimination des Antibiotikums Cephacetril bei Patienten mit eingeschränkter Nierenfunktion. Schweiz Med Wochenschr 103:783, 1973PubMedGoogle Scholar

Main references

  1. Berman SJ, Boughton WH, Sugihara JJ, Wong EGC, Sato MM, Siemens AW: Pharmacokinetics of cefaclor in patients with end stage renal disease during hemodialysis. Antimicrob Agents Chemother 14:281, 1978PubMedCrossRefGoogle Scholar
  2. Bloch R, Szwed JJ, Sloan RS, Luft FC: Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure. Antimicrob Agents Chemother 12:730, 1977PubMedCrossRefGoogle Scholar
  3. Fillastre J, Leroy A, Humber G, Godin M: Cefaclor pharmacokinetics and renal impairment. J Antimicrob Chemother 6:155, 1980PubMedCrossRefGoogle Scholar
  4. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobil agents by GL Mandell and MA SandeGoogle Scholar
  5. Levison ME, Santoro J, Agarwal BN: In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure. Postgrad Med J 55:12, 1979PubMedGoogle Scholar
  6. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:142, cefaclor.Google Scholar
  7. Meyers BR, Hirschman SZ, Wormser G, Gartenberg G, Srulevippel E: Pharmacologic studies with cefaclor, a new oral cephalosporin. J Clin Pharmacol 18:174, 1978PubMedGoogle Scholar
  8. Pommer W, Krause PH, Berg PA, Neumayer H H, Mihatsch MJ, Molzahn M: Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment. Klin Wochenschr 64:290, 1986PubMedCrossRefGoogle Scholar
  9. Santoro J, Agarwal BN, Martinelli R, Wenger N, Levison ME: Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob Agents Chemother 13:951, 1978PubMedCrossRefGoogle Scholar
  10. Spyker DA, Gober LL, Scheld WM, Sande MA, Bolton WK: Pharmacokinetics of cefaclor in renal failure: Effects of multiple doses and hemodialysis. Antimicrob Agents Chemother 21:278, 1982PubMedCrossRefGoogle Scholar

Main references

  1. Cutler RE, Blair AD, Kelly MR: Cefadroxil kinetics in patients with renal insufficiency. Clin Pharmacol Ther 25:514, 1979PubMedGoogle Scholar
  2. Ginsburg CM, McCracken GH jr, Clahsen JC, Thomas ML: Clinical pharmacology of cefadroxil in infants and children. Antimicrob Agents Chemother 13:845, 1978PubMedCrossRefGoogle Scholar
  3. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA SandeGoogle Scholar
  4. Humbert G, Leroy A, Fillastre J, Godin M: Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Chemotherapy 25:189, 1979PubMedCrossRefGoogle Scholar
  5. Jolly ER, Henness DM, Richards D jr: Human safety tolerance and pharmacokinetic studies of cefadroxil, a new cephalosporin antibiotic for oral administration. Curr Ther Res 22:727, 1977Google Scholar
  6. Pfeffer M, Jackson A, Ximenes J, De Menezes JP: Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephadrine. Antimicrob Agents Chemother 11:331, 1977PubMedCrossRefGoogle Scholar

Main references

  1. Andriole VT: Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. J Infect Dis 137 (Suppl): S88, 1978PubMedCrossRefGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:176, cefaloridine.Google Scholar
  3. Nightingale CH, Greene DS, Quintiliani R: Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci 64:1899, 1975PubMedCrossRefGoogle Scholar

Main references

  1. Ahem MJ, Finkelstein FO, Andriole VT: Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother 10:457, 1976CrossRefGoogle Scholar
  2. Appel GB, Neu HC, Parry MF, Goldberger MJ, Jacob GB: Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis. Antimicrob Agents Chemother 10:623, 1976PubMedCrossRefGoogle Scholar
  3. Brogard JM, Kopferschmitt J, Spach MO, Grudet O, Lavillaureix J: Cefamandole pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol 19:366, 1979PubMedGoogle Scholar
  4. Campillo JA, Lanao JM, Dominguez-Gil A, Tabernero JM, Rubio F: Pharmacokinetics of cephamandole in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm 17:416, 1979PubMedGoogle Scholar
  5. Czerwinski AW, Pederson JA: Pharmacokinetcs of cefamandole in patients with renal impairment. Antimicrob Agents Chemother 15:161, 1979PubMedCrossRefGoogle Scholar
  6. Gambertoglio JG, Aziz NS, Lin ET, Grausz H, Naughton JL, Benet LZ: Cefamandole kinetics in uremic patients undergoing hemodialysis. Clin Pharmacol Ther 26:592, 1979PubMedGoogle Scholar
  7. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA SandeGoogle Scholar
  8. Janicke DM, Morse GD, Apicella M, Jusko WJ, Walshe JJ: Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther 40:209, 1986PubMedCrossRefGoogle Scholar
  9. Martindale. The extra pharmacopeia. 29th ed. London: The Pharmaceutical Press, 1989:179, cefamandoleGoogle Scholar
  10. McAllister TA, Mocan H, Murphy AV, Beattie TJ: Antibiotic susceptibility of staphylococci from CAPD peritonitis in children. J Antimicrob Chemother 19:95, 1987PubMedCrossRefGoogle Scholar
  11. Morse GD, Rowinski C, Lieveld PE, Walshe JJ: Drug-protein binding during continuous ambulatory peritoneal dialysis. Perit Dial Bull 6:144, 1986Google Scholar
  12. Neu H: Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis 137:580, 1978CrossRefGoogle Scholar
  13. Pancorbo S, Comty C: Pharmacokinetics of cefamandole in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Bull 3:135, 1983Google Scholar
  14. Scott DK, Roberts DE: Drugs and continuous peritoneal dialysis (Part 2). Pharm J 234:621, 1985Google Scholar

Main references

  1. Lange H, Dapper FD, Baier R: Pharmakokinetik und Dosierung von Cefazedon bei Dialysepatienten. Klinikarzt 11:409, 1982Google Scholar
  2. Pabst J, Leopold G, Ungethüm W, Dingeldein E: Clinical pharmacology phase 1 of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin. Arzneimittelforschung (Drug Res) 29(I):437, 1979Google Scholar
  3. Ungethüm W, Pabst J, Dingeldein E, Leopold G: Clinical pharmacology phase 1 of cefazedone, a new cephalosporin in healthy volunteers. III. Investigations of the mechanism of renal elimination. Arzneimittelforschung (Drug Res) 29(0:443, 1979Google Scholar

Main references

  1. Brogard JM, Pinget M, Brandt C, Lavillaureix J: Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis. J Clin Pharmacol 17:225, 1977PubMedCrossRefGoogle Scholar
  2. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33:66, 1983PubMedCrossRefGoogle Scholar
  3. Craig CP, Rifkin SI: Pharmacokinetics and hemodialyzability of cefazolin in uremic patients. Clin Pharmacol Ther 19:825, 1976PubMedGoogle Scholar
  4. Craig WA, Welling PG, Jackson TC, Kunin CM: Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis 128 (Suppl):S347, 1973PubMedCrossRefGoogle Scholar
  5. Czerwinski AW, Pederson JA, Barry JP: Cefazolin plasma concentrations and urinary excretion in patients with renal impairment. J Clin Pharmacol 14:560, 1974PubMedGoogle Scholar
  6. Eastwood JB, Gower PE, Curtis JR: The serum half-life and urine concentration of cefazolin sodium in patients with terminal renal failure: Effect of haemodialysis. Scoff Med J 20:240, 1975Google Scholar
  7. Greene DS, Tice AD: Effect of hemodialysis on cefazolin protein binding. J Pharm Sci 66:1508, 1977PubMedCrossRefGoogle Scholar
  8. Hiner LB, Baluarte HJ, Polinsky MS, Gruskin AB: Cefazolin in children with renal insufficiency. J Pediatr 96:335, 1980PubMedCrossRefGoogle Scholar
  9. Kaye D, Wenger N, Agarwal B: Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis. Antimicrob Agents Chemother 14:318, 1978PubMedCrossRefGoogle Scholar
  10. Kirby WMM, Regamey C: Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 128 (Suppl):S341, 1973PubMedCrossRefGoogle Scholar
  11. Levison ME, Levison SP, Ries K, Kaye D: Pharmacology of cefazolin in patients with normal and abnormal renal function. J Infect Dis 128 (Suppl):S354, 1973PubMedCrossRefGoogle Scholar
  12. Madhavan T, Yaremchuk K, Levin N, Fisher E, Cox F, Burch K, Haas E, Pohlod D, Quinn EL: Effects of renal failure and dialysis on cefazolin pharmacokinetics. Antimicrob Agents Chemother 8:63, 1975PubMedCrossRefGoogle Scholar
  13. McCloskey RV, Forland MF, Sweeney MJ, Lawrence DN: Hemodialysis of cefazolin. J Infect Dis 128 (Suppl):S358, 1973PubMedCrossRefGoogle Scholar
  14. Quintiliani R, Nightingale CH: Cefazolin. Ann Intern Med 89 (Part 1):650, 1978PubMedGoogle Scholar
  15. Rein MF, Westervelt FB, Sande MA: Pharmacodynamics of cefazolin in the presence of normal and impaired renal function. Antimicrob Agents Chemother 4:366, 1973PubMedCrossRefGoogle Scholar
  16. Sack K, Wilhelm J: Klinische Verlaufsstudie zur Nierenträglichkeit von Cefazolin. Infection 2 (Suppl 1):68, 1974Google Scholar
  17. Welling PG, Craig WA, Amidon GL, Kunin CM: Pharmacokinetics of cefazolin in normal and uremic subjects. Clin Pharmacol Ther 15:344, 1974PubMedGoogle Scholar

Main reference

  1. Guay DRP, Meatherall RC, Harding GK, Brown GR: Pharmacokinetics of cefixime (CL 284, 635, FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 30:485, 1986PubMedCrossRefGoogle Scholar

Main references

  1. Gambertoglio JG, Alexander DP, Barriere SL: Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal isufficiency and on hemodialysis. Antimicrob Agents Chemother 26:845, 1984PubMedCrossRefGoogle Scholar
  2. Polk RE, Sica DA, Kerkering TM, Kline BJ, Patterson PM, Baggett JW: Cefmenoxime pharmacokinetics in patients with renal insufficiency. Antimicrob Agents Chemother 26:322, 1984PubMedCrossRefGoogle Scholar
  3. Sica DA, Polk RE, Kerkering TM, Patterson PM, Baggett JW: Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 30:713, 1986PubMedCrossRefGoogle Scholar

Main references

  1. Barriere SL, Gambertoglio JG, Alexander DP, Stagg RJ, Conte JE jr: Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis. Rev Infect Dis 6 (Suppl 4):S809, 1984PubMedCrossRefGoogle Scholar
  2. Blair AD, Maxwell BM, Forland SC, Jacob L, Cutler RE: Cefonicid kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 35:798, 1984PubMedCrossRefGoogle Scholar
  3. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50. Antimicrobial agents by GL Mandell and MA SandeGoogle Scholar
  4. Morse GD, Lane T, Nairn DK, Deterding J, Curry J, Gal P: Peritoneal transport of cefonicid. Antimicrob Agents Chemother 31:292, 1987PubMedCrossRefGoogle Scholar
  5. Phelps RT, Conte JE: Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function. Antimicrob Agents Chemother 29:913, 1986PubMedCrossRefGoogle Scholar
  6. Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R: Kinetics and renal handling of cefonicid. Clin Pharmacol Ther 30:587, 1981PubMedCrossRefGoogle Scholar

Main references

  1. Allaz AF, Dayer P, Fabre J, Rudhardt M, Balant L: Pharmaco-cinetique d’une nouvelle cephalosporine, la cefoperazone. Schweiz Med Wochenschr 109:1999, 1979Google Scholar
  2. Bolton WK, Scheld WM, Spyker DA, Sande MA: Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother 19:821, 1981PubMedCrossRefGoogle Scholar
  3. Greenfield RA, Gerber AU, Craig WA: Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis 5 (Suppl):S127, 1983PubMedCrossRefGoogle Scholar
  4. Hodler JE, Galeazzi RL, Frey B, Rudhardt M, Seiler AJ: Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: Clinical and pathophysiological implications. Eur J Clin Pharmacol 26:609, 1984PubMedCrossRefGoogle Scholar
  5. Jendroschek T, Belmega G, Lode H, Kemmerich B, Dzwillo G, Koeppe P, Wagner J: Ein neues Breitband-Antibiotikum. Med Klin 76:102, 1981PubMedGoogle Scholar
  6. Keller E, Jansen A, Pelz K, Hoppe-Seyler G, Schollmeyer P: Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 35:208, 1984PubMedCrossRefGoogle Scholar
  7. Spyker DA, Richmond JD, Scheld WM, Bolton WK: Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients. Am J Nephrol 5:355, 1985PubMedCrossRefGoogle Scholar
  8. Trollfors B, Ahlem J, Alestig K: Renal function during cefoperazone treatment. J Antimicrob Chemother 9:485, 1982PubMedCrossRefGoogle Scholar

Main references

  1. Estey EH, Weaver SS, LeBlanc BM, Brown N, Ho DH, Bodey GP: Ceforanide kinetics. Clin Pharmacol Ther 30:398, 1981CrossRefGoogle Scholar
  2. Hawkins SS, Alford RH, Stone WJ, Smyth RD, Pfeffer M: Ceforanide kinetics in renal insufficiency. Clin Pharmacol Ther 30:468, 1981PubMedCrossRefGoogle Scholar
  3. Hess JR, Berman SJ, Boughton WH, Sugihara JG, Musgrave JE, Wong EGC, Siemens AM: Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis. Antimicrob Agents Chemother 17:251, 1980PubMedCrossRefGoogle Scholar
  4. Lanao JM, De Prada CR, Dominguez-Gil A, Tabernero JM, Martin J, Gomez JR: Ceforanide pharmacokinetics in haemodialysis: The effect of ultrafiltration. Biopharm Drug Dispos 7:335, 1986PubMedCrossRefGoogle Scholar

Main references

  1. Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C: Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 38:285, 1985PubMedCrossRefGoogle Scholar
  2. Baier R, Furkert D, Frei M, Dapper D, Lange H: Pharmakokinetik von Cefotaxim bei Patienten unter chronischer Hämodialyse-behandlung. Nieren- und Hochdruckkrankh 12:114, 1983Google Scholar
  3. Chodos J, Francke EL, Saltzman M, Neu HC: Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis. Ther Drug Monit 3:71, 1981PubMedGoogle Scholar
  4. Doluisio JT; Clinical pharmacokinetics of cefotaxime in patients with normal and impaired renal function. Rev Infect Dis 4 (Suppl): S333, 1982PubMedCrossRefGoogle Scholar
  5. Fu UP, Aswapokee P, Ho I, Matthijssen C, Neu HC: Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 16:592, 1979PubMedCrossRefGoogle Scholar
  6. Heim KL, Halstenson CE, Comty CM, Affrime MB, Matzke GR: Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 30:15, 1986PubMedCrossRefGoogle Scholar
  7. Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G: The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal fuction. Rev Infect Dis 4 (Suppl):S379, 1982PubMedCrossRefGoogle Scholar
  8. Glöckner WM, Kindler J, Höffer U, Peters G, Siebert HG: Pharmakokinetik von Cefotaxim bei Patienten mit dialysepflichtiger Niereninsuffizienz. Infection 8:S430, 1980CrossRefGoogle Scholar
  9. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:151, cefotaxime sodiumGoogle Scholar
  10. Matzke GR, Abraham PA, Halstenson CE, Keane WF: Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther 38:31. 1985PubMedCrossRefGoogle Scholar
  11. Ohkawa M, Okasho A, Motoi I, Tokunaga S, Shoda R, Kawaguchi S, Sawaki M, Shimamura M, Hirano S, Kuroda K, Awazu S: Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis. Chemotherapy 29:4, 1983PubMedCrossRefGoogle Scholar
  12. Petersen J, Stewart RD, Catto GR, Edward N: Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in parients on continuous ambulatory peritoneal dialysis. Nephron 40:79, 1985PubMedCrossRefGoogle Scholar
  13. Wise R, Wright N, Wills PJ: Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrob Agents Chemother 19:526, 1981PubMedCrossRefGoogle Scholar

Main references

  1. Browning M, Chapman S, Cockshott ID, White L, Yates RA: Pharmacokinetics of cefotetan in patients requiring chronic ambulatory peritoneal dialysis. In: Lode H, Periti P, Strachan CJ, (eds): Cefotetan: A long-acting antibiotic. Edinburgh: Churchill Livingstone, 1985 p 106Google Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Phrmaceutical Press. 1989:156, cefotetan disodiumGoogle Scholar
  3. Ohkawa M, Hirano S, Tokunaga S, et al.: Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother 23:31, 1983PubMedCrossRefGoogle Scholar
  4. Smith BR, LeFrock JL, Thyrum PT, Doret BA, Yeh C, Onesti G, Schwartz A, Zimmerman JJ: Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrob Agents Chemother 29:887, 1986PubMedCrossRefGoogle Scholar
  5. Ward A, Richards DM: Cefotetan: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic uses. Drugs 30:382, 1985PubMedCrossRefGoogle Scholar

Main references

  1. Alonso IG, Matino EL, Dominguez-Gil A, Tabernero JM: Pharmacokinetics of cefotiam during hemofiltration. Int J Clin Pharmacol Ther Toxicol 24:359, 1986PubMedGoogle Scholar
  2. Konishi K, Ozawa Y: Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother 26:647, 1984PubMedCrossRefGoogle Scholar
  3. Lecaillon JB, Rouan MC, Binswanger U, Guibert J, Schoeller JP: Pharmacokinetics of cefotiam and cefsulodin after simultaneous administration to patients with impaired renal function. Antimicrob Agents Chemother 26:368, 1984PubMedCrossRefGoogle Scholar
  4. Rouan MC, Binswanger U, Bammatter F, Theobaldt W, Schoeller JP, Guibert J: Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients. J. Antimicrob Chemother 19:611, 1984CrossRefGoogle Scholar

Main references

  1. Arvidsson A, Alvan G, Tranaeus A, Malmborg AS: Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 28:333, 1985PubMedCrossRefGoogle Scholar
  2. Brogden RN, Heel RC, Speight TM, Avery GS: Cefoxitin: A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 17:1, 1979PubMedCrossRefGoogle Scholar
  3. Fillastre JP, Leroy A, Godin M, Oksenhendler G, Humbert G: Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother 4(B):79, 1978PubMedCrossRefGoogle Scholar
  4. Garcia MJ, Dominguez-Gil A, Tabernero JM, Tomero JAS: Pharmacokinetics of cefoxitin in patients with normal and impaired renal function. Eur J Clin Pharmacol 16:119, 1979PubMedCrossRefGoogle Scholar
  5. Garcia MJ, Dominguez-Gil A, Tabernero JM, Bondia Roman A: Pharmacokinetics of cefoxitin in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm 17:366, 1979PubMedGoogle Scholar
  6. Garcia MJ, Dominguez-Gil A, Tabernero JM, Diaz Molina M: Pharmacokinetics of cefoxitin during haemofiltration. Eur J Clin Pharmacol 25:395, 1983PubMedCrossRefGoogle Scholar
  7. Greaves WL, Kreeft JH, Ogilvie RI, Richards GK: Cefoxitin disposition during peritoneal dialysis. Antimicrob Agents Chemother 19:253, 1981PubMedCrossRefGoogle Scholar
  8. Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C: Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. Rev Infect Dis 1:118, 1979PubMedCrossRefGoogle Scholar
  9. Lange H, Puppel H, Trost G: Pharmakokinetik von Cefoxitin unter Dialysebehandlung. Infection 7 (Suppl 1):S76, 1979CrossRefGoogle Scholar
  10. Saah AJ, Koch TR, Drusano GL; Cefoxitin falsely elevates creatinine levels. JAMA 247:205, 1982PubMedCrossRefGoogle Scholar
  11. Schrogie J, Davies R, Yeh K et al.: Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother 4(B):69, 1978PubMedCrossRefGoogle Scholar
  12. Vlasses PH, D’Silva H, Rocci ML jr, Koplin JR, Bland JA, Sici-liano EG, Ferguson RK: Disposition of intravenous and intraperitoneal cefoxitin during chronic intermittent peritoneal dialysis. Am J Kidney Dis 3:67, 1983PubMedGoogle Scholar
  13. Wise R, Donovan IA, Ambrose NS, Allcock JE: The penetration of cefoxitin into peritoneal fluid. J Antimicrob Chemother 8:453, 1981PubMedCrossRefGoogle Scholar

Main references

  1. Bergan T, Brodwall EK, Larsen EW: Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function. Chemotherapy 29:163, 1983PubMedCrossRefGoogle Scholar
  2. Nieto MJ, Lanao JM, Dominguez-Gil A, Tabernero JM, Macias JF: Elimination of cefroxadine (CGP-9000) from patients indergoing dialysis. Eur J Clin Pharmacol 24:109, 1983PubMedCrossRefGoogle Scholar
  3. Ohkawa M, Takamae K, Shimamura M et al.: Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function. Chemotherapy 27:149, 1981PubMedCrossRefGoogle Scholar

Main references

  1. Gibson TP, Granneman GR, Kallal JE, Sennello LT: Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther 31:602, 1982PubMedCrossRefGoogle Scholar
  2. Gillespie WR, Veng-Pedersen P, Gibson TP: Deconvolution applied to the kinetics of extracorporal drug removal. Hemodialysis of cefsulodin. Eur J Clin Pharmacol 29:503, 1985PubMedCrossRefGoogle Scholar
  3. Granneman GR, Sennello LT, Sonders RC, Wynne B, Thomas EW: Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clin Pharmacol Ther 31:95, 1982PubMedCrossRefGoogle Scholar
  4. Matzke GR, Keane WF: Cefsulodin pharmacokinetics during hemodialysis. Trans Am Soc Artif Intern Organs 28:324, 1982PubMedGoogle Scholar

Main references

  1. Ackerman BH, Ross J, Tofte RW, Rotschafer JC: Effect of decreased renal function on the pharmacokinetics of ceftazidime. Antimicrob Agents Chemother 25:785, 1984PubMedCrossRefGoogle Scholar
  2. Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humber G: Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother 25:638, 1984PubMedCrossRefGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:162, ceftazidime.Google Scholar
  4. Nikolaidis P, Tourkantonis A: Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 24:142, 1985PubMedGoogle Scholar
  5. Tourkantonis A, Nikolaidis P: Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. J Antimicrob Chemother 12 (Suppl A):263,1983PubMedCrossRefGoogle Scholar
  6. Van Dalen R, Vree TB, Baars AM, Termond E: Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol 30:597, 1986PubMedCrossRefGoogle Scholar

Main references

  1. Burgess ED, Blair AD: Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 24:237, 1983PubMedCrossRefGoogle Scholar
  2. Dubb J, Actor P, Pirkin D et al.: Ceftizoxime kinetics and renal handling. Clin Pharmaco Ther 31:516, 1982CrossRefGoogle Scholar
  3. Gross ML, Somani P, Ribner BS, Raeader R, Freimer EH, Higgins JT jr: Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34:673, 1983PubMedCrossRefGoogle Scholar
  4. Johnson CA, Zimmerman SW, Bayer W, Craig WA: Pharmacokinetics of intravenous ceftizoxime in patients in continuous ambulatory peritoneal dialysis. Clin Nephrol 23:120, 1985PubMedGoogle Scholar
  5. Kowalsky SF, Echols RM, Venezia AR, Andrews EA: Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function. Antimicrob Agents Chemother 24:151, 1983PubMedCrossRefGoogle Scholar
  6. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:166, ceftizoxime sodiumGoogle Scholar
  7. Ohkawa M, Okasho A, Sugata T et al.: Elimination kinetics of ceftizoxime in humans with and without renal insufficiency. Antimicrob Agents Chemother 22:308, 1982PubMedCrossRefGoogle Scholar
  8. Shah PM, Knobloch M, Haag R, Kühnle HF: Pharmacokinetics of ceftizoxime in patients undergoing hemodialysis. Methods Find Exp Clin Pharmacol 4:185, 1982PubMedGoogle Scholar

Main reference

  1. Albin H, Ragnaud JM, Demotes-Mainard F, Vincon G, Couzineau M, Wone C: Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 31:479, 1986PubMedCrossRefGoogle Scholar
  2. Cohen D, Appel GB, Scully B, Neu HC: Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother 24:529, 1983PubMedCrossRefGoogle Scholar
  3. Koup JR, Keller E, Neumann H, Stoeckel K: Ceftriaxone pharmacokinetics during peritoneal dialysis. Eur J Clin Pharmacol 30:303, 1986PubMedCrossRefGoogle Scholar
  4. Patel IH, Sugihara JG, Weinfeld RE, Wong EGC, Siemsen AW, Berman SJ: Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 25:438, 1984PubMedCrossRefGoogle Scholar
  5. Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E: Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther 33:633, 1983PubMedCrossRefGoogle Scholar
  6. Stoeckel K, Koup JR: Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med 77(4c):26, 1984PubMedGoogle Scholar
  7. Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ: Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 25:83, 1984PubMedCrossRefGoogle Scholar

Main references

  1. Brown G: Die Pharmakokinetik von Cefuroxim-Axetil. Fortschr Antimikrob Antineoplast Chemother 6-8:1319, 1987Google Scholar
  2. Bundtzen RW, Toothaker RD, Nielson OS, Madsen PO, Welling PG, Craig WA: Pharmacokinetics of cefuroxime in normal and impaired renal function: Comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother 19:443, 1981PubMedCrossRefGoogle Scholar
  3. Chan MK, Browning AK, Poole CJ, Matheson LA. Li CS, Baillod, RA: Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis. Nephron 41:161, 1985PubMedCrossRefGoogle Scholar
  4. Cox CE, Sherrill JM, Cocchetto DM: Evaluation of cefuroxime axetil, cefaclor and cephalexin in the treatment of urinary tract infections in adults. Curr Ther Res 42:124, 1987Google Scholar
  5. van Dalen R, Vree TB, Hafkenscheid JC, Gimbrere JS: Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency. J Antimicrob Chemother 5:281, 1979PubMedCrossRefGoogle Scholar
  6. Foord RD: Cefuroxime: Human pharmacokinetics. Antimicrob Agents Chemother 9:741, 1976PubMedCrossRefGoogle Scholar
  7. Gower PE, Dash CM: The pharmacokinetics of cefuroxime after intravenous injection. Eur J Clin Pharmacol 12:221, 1977PubMedCrossRefGoogle Scholar
  8. Harding SM, Williams Peo, Ayrton J: Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother 25: 78, 1984PubMedCrossRefGoogle Scholar
  9. Kosmidis J, Stathakis C, Anyfantis A, Daikos GK: Cefuroxime in renal insufficiency: Therapeutic results in various infections and pharmacokinetics including the effect of dialysis. Proc Roy Soc Med 70 (Suppl 9): 139, 1977PubMedGoogle Scholar
  10. LaGreca G, Biasioli S, Chiaramonte S, et al.: Pharmacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis. Int J Clin Pharmacol Ther Toxicol 20:92, 1982Google Scholar
  11. Local FK, Munro AJ, Kerr DNS, Sussman M: Pharmacokinetics of intravenous and intraperitoneal cefuroxime in patients undergoing peritoneal dialysis. Clin Nephrol 16:40, 1981PubMedGoogle Scholar
  12. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:170, cefuroxime axetilGoogle Scholar
  13. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:171,  cefuroxime sodiumGoogle Scholar
  14. Marx MA, Fant WK: Cefuroxime axetil. Drug Intel Clin Pharm 22:651, 1988Google Scholar
  15. Neu HC, Fu KP: Cefuroxime, a beta-lactamase resistent cephalosporin with a broad spectrum of Grampositive and Gramnegative activity. Antimicrob Agents Chemother 13:657, 1978PubMedCrossRefGoogle Scholar
  16. Sommers DK, van Wyk MV, Williams PEO, Harding SM: Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 25:344, 1984PubMedCrossRefGoogle Scholar
  17. Trollfors B, Suurkula M, Price JD, Norrby R: Renal function during cefuroxime treatment in patients with pre-existing renal impairment. J Antimicrob Chemother 6:665, 1980PubMedCrossRefGoogle Scholar
  18. Walstad RA, Nilsen DG, Berg KJ: Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. Eur J Clin Pharmacol 24:391, 1983PubMedCrossRefGoogle Scholar
  19. Wise R, Bennett SA, Dent J: The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 13:603, 1984PubMedCrossRefGoogle Scholar

Main references

  1. Caruso FS, Doshan HD, Hernandez PH, Costello R, Applin W, Neiss ES: Celiprolol: Pharmacokinetics and duration of pharmacodynamic activity. Br J Clin Pract 39 (Suppl 40): 12, 1985Google Scholar
  2. Hitzenberger G, Takacs F, Pittner H: Pharmakokinetik des Beta-Rezeptorenblockers Celiprolol nach einmaliger intravenöser und oraler Gabe am Menschen. Arzneimittelforschung (Drug Res) 33:50, 1983Google Scholar
  3. Schmidt P, Takacs F, Pittner H, Minar E, Balcke P, Zazgornik J, Deutsch E: Vergleichende Pharmakokinetik des Beta 1-Rezeptoren-Blockers Celiprolol nach oraler Einzelgabe an Nierengesunde und an Patienten mit eingeschränkter Nierenfunktion. Wien Klin Wochenschr 97:729, 1985PubMedGoogle Scholar

Main references

  1. Bailey RR, Gower PE, Dash CH: The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin. Postgrad Med J 46 (Suppl September):60, 1970Google Scholar
  2. Brogard JM, Pinget M, Dorner M, Lavillaureix J: Determination of cefalexin pharmacokinetics and dosage adjustment in relation to renal function. J Clin Pharmacol 15:666, 1975PubMedGoogle Scholar
  3. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33:66, 1983PubMedCrossRefGoogle Scholar
  4. Butcher RH, Dawborn JK, Pattison G: Blood and urine levels of cephalexin in patients with impaired renal function. Med J Aust 2:1282, 1972PubMedGoogle Scholar
  5. Drew PJT, Casewell MW, Desai N, Houang ET, Simpson CN, Marsh FP: Cephalexin for the oral treatment of CAPD peritonitis. J Antimicrob Chemother 13:153, 1984PubMedCrossRefGoogle Scholar
  6. Griffith RS: The pharmacology of cephalexin. Postgrad Med J 59 (Suppl 5): 16, 1983PubMedGoogle Scholar
  7. Hori R, Okumura K, Kamiya A, Nihira H, Nakano H: Ampicillin and cephalexin in renal insufficiency. Clin Pharmacol Ther 34:792, 1983PubMedCrossRefGoogle Scholar
  8. Kabins SA, Kelner B, Walton E et al.: Cephalexin therapy as related to renal function. Am J Med Sci 259:133, 1970PubMedCrossRefGoogle Scholar
  9. Kunin CM, Finkelberg Z: Oral cephalexin and ampicillin: Antimicrobial activity, recovery in urine, and persistence in blood of uremic patients. Ann Intern Med 72:349, 1970PubMedGoogle Scholar
  10. Linquist JA, Siddiqui JY, Smith JM: Cephalexin in patients with renal disease. N Engl J Med 283:720, 1970PubMedCrossRefGoogle Scholar
  11. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:173,  cephalexin.Google Scholar
  12. Regamey C, Hamair L: Pharmacokinetics of cephalexin in renal insufficiency. Postgrad Med J 47 (Febr Suppl):69, 1971PubMedGoogle Scholar
  13. Reisberg BE, Mandelbaum JM: Cephalexin: absorption and excretion as related to renal function and hemodialysis. Infect Immun 3:540, 1971PubMedGoogle Scholar
  14. Sennesael J, Verbeelen D, Lauwers S: Ototoxicity associated with cephalexin in two patients with renal failure. Lancet II: 1154, 1982CrossRefGoogle Scholar

Main references

  1. Burton JR, Lichtenstein NS, Colvin RB et al.: Acute renal failure during cephalothin therapy. JAMA 229:679, 1974PubMedCrossRefGoogle Scholar
  2. Höffler D, Koeppe P, Fuchs E, Fiegel P: Cephalotin-Plasmaspiegel bei normaler und eingeschränkter Nierenfunktion. Int J Clin Pharmacol Ther Toxicol 5(4):450, 1972Google Scholar
  3. Kabins SA, Cohen S: Cephalotin serum levels in the azotemic patient. Antimicrob Agents Chemother 4:207, 1964Google Scholar
  4. Kirby WMM, DeMaine JB, Serrill WS: Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients. Postgrad Med J 47 (Suppl Febr):41, 1971PubMedGoogle Scholar
  5. Kunin CM, Atuk N: Excretion of cephaloridine and cephalothin in patients with renal impairment. N Engl J Med 274:654, 1966PubMedCrossRefGoogle Scholar
  6. Münch R, Steurer J, Lüthy R, Siegenthaler W, Kuhlmann U: Serum and dialyzate concentrations of intraperitoneal cephalothin in patients undergoing continuous ambulatory peritoneal dialysis. Clin Nephrol 20:40, 1983PubMedGoogle Scholar
  7. Pasternak DP, Stephens BG: Reversible nephrotoxicity associated with cephalothin therapy. Arch Intern Med 135:599, 1975PubMedCrossRefGoogle Scholar
  8. Perkins RL, Smith EJ, Saslaw S: Cephalothin and cephaloridine: Comparative pharmacodynamics in chronic uremia. Am J Med Sci 257:116, 1969PubMedCrossRefGoogle Scholar
  9. Pickering MJ, Spooner GR, De Quesade A et al.: Declining renal function associated with administration of cephalothin. South Med J 63:426, 1970PubMedCrossRefGoogle Scholar
  10. Rankin L, Swain R, Luft F: Effect of cephalothin on measurement of creatinine concentration. Antimicrob Agents Chemother 15:666, 1979PubMedCrossRefGoogle Scholar
  11. Sanders WE jr, Johnson JE III, Taggart JG: Adverse reactions to cephalothin and cephapirin: Uniform occurrence on prolonged intravenous administration of high doses. N Engl J Med 290:424. 1974PubMedCrossRefGoogle Scholar
  12. Schulte-Lippern M, Freyland MD, Frotscher U, Jenett G, Messerschmidt W, Richter R, Zschaege B, Wilbrand R: Akutes Nierenversagen nach hochdosierter Cephalotinbehandlung. Med Klin 68:202, 1973PubMedGoogle Scholar
  13. Spyker DA, Thomas BL, Sande MA, Bolton WK: Pharmacokinetics of cefaclor and cephalexin. Dosage nomograms for impaired renal function. Antimicrob Agents Chemother 14:172, 1978PubMedCrossRefGoogle Scholar
  14. Tourkantonis A, Mössner G, Egetmeyer KA, Heinze V: Cephalotin concentration during haemo- and peritoneal dialysis. Proc Eur Dial Transplant Assoc 5:353, 1969Google Scholar
  15. Venuto RC, Plaut M: Cephalothin handling in patients undergoing hemodialysis. Antimicrob Agents Chemother 10:50, 1970PubMedGoogle Scholar
  16. Wilson FM, Retan JW, Lerner AM: Clinical studies with cephalothin. J Urol 96:534, 1966PubMedGoogle Scholar

Main references

  1. Arvidsson A, Borga D, Alvan G: Renal excretion of cephapirin and cephaloridine: Evidence for saturable tubular reabsorption. Clin Pharmacol Ther 25:870, 1979PubMedGoogle Scholar
  2. Axelrod J, Meyers BR, Hirschman SZ: Cephapirin: pharmacology in normal human volunteers. J Clin Pharmacol 12:81, 1972Google Scholar
  3. Bergan T, Orjavik D, Brodwall EK: Pharmacokinetics of cefapirin in patients with normal and impaired renal function. Arzneimittelforschung (Drug Res) 31:1773, 1981Google Scholar
  4. Bran JL, Levinson ME, Kaye D: Clinical and in vitro evaluation of cephapirin, a new cephalosporin antibiotic. Antimicrob Agents Chemother 1:35, 1972PubMedCrossRefGoogle Scholar
  5. Cabana BE, Van Harben DR, Hottendorf GH et al.: The role of the kidney in the elimination of cephapirin in man. J Pharmacokinet Biopharm 3:419, 1975PubMedGoogle Scholar
  6. McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF: Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium. Antimicrob Agents Chemother 1:90, 1972PubMedCrossRefGoogle Scholar

Main references

  1. Anastassiades EG and Curtis JR: In: Cephradine 12 years on -a routine antibiotic for therapy and prophylaxis. International congress and symposium series No. 85, A Percival and P Woods (eds), London: The Royal Society of Medicine, 1985 p 55Google Scholar
  2. Boeschoten EW, Rietra PJGM, Krediet RT, Visser MJ, Arisz L: CAPD peritonitis: A prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 16:789, 1985PubMedCrossRefGoogle Scholar
  3. Höffler D, Koeppe P: Zur Pharmakokinetik intravenös applizierten Cefradins bei normaler und eingeschränkter Nierenfunktion. Münchn Med Wochenschr 117:1169, 1975Google Scholar
  4. Johnson CA, Welling PG, Zimmerman SW: Pharmacokinetics of oral cephradine in continuous ambulatory peritoneal dialysis patients. Nephron 38:57, 1984PubMedCrossRefGoogle Scholar
  5. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:184, cephradine.Google Scholar
  6. Minn FL, Sugerman AA, Bernfeld CE: Cephradine excretion in humans with pH-altered urine. J Clin Pharmacol 16:171, 1976PubMedGoogle Scholar
  7. Raman GV: In: Cephradine 12 years on — a routine antibiotic for therapy and prophylaxis, International congress and symposium series No. 85, A Percival and P Woods (eds), London: The Royal Society of Medicine, 1985 p 47Google Scholar
  8. Searle M, Raman GV: Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 23:241, 1985PubMedGoogle Scholar
  9. Solomon AE, Buggs JD, McGleachy R, et al.: The administration of cephradine to patients in renal failure. Br J Clin Pharmacol 2:443, 1975PubMedCrossRefGoogle Scholar

Main references

  1. De Caro G, Improta G: Disappearance of Caerulein from circulating blood and its inactivation in vitro by tissue homogenates and blood of dogs and rats. Arch Int Pharmacodyn Ther 197:166, 1972PubMedGoogle Scholar
  2. Erspamer V: Caerulein aus Amphibienhaut. Ein Analogon des Säugetiercholezystokinins. Therapiewoche 31:2690, 1981Google Scholar
  3. Go VLW: The physiology of cholecystokinin. In: Bloom SR (ed): Gut hormones, Edinburgh, London, New York: Churchill Livingstone, 1978 p 203Google Scholar
  4. Robberecht P, Cremer M, Vandermeers A, Vandermeers-Piret MC, Cotton P, De Neef P, Christophe J: Pancreatic secretion of total protein and of three hydrolases collected in healthy subjects via duodenoscopic cannulation. Effects of secretin, pancreozymin, and caerulein. Gastroenterology 69:374, 1975PubMedGoogle Scholar
  5. Tokiwa T, Uemura I, Murakami H, Tsuruoka S, Kaneko M, Ogawa K, Manzai T: Studies on Caerulein (Fl 6934). Absorption, distribution, metabolism and excretion of caerulein. Jpn J Pharmacol 25:747, 1975PubMedCrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1555, chenodeoxycholic acid.Google Scholar

Main references

  1. Berry DJ: Determination of trichloroethanol at therapeutic and overdose levels in blood and urine by electron capture gas chromatography. J Chromatogr 107:107, 1975PubMedCrossRefGoogle Scholar
  2. Mackay FJ, Cooper JR: A study on the hypnotic activity of chloral hydrate. J Pharmacol Exp Ther 135:271, 1962PubMedGoogle Scholar
  3. Marshall EL jr, Owens AH jr: Absorption, excretion, and metabolic fate of chloral hydrate and trichloroethanol. Bull Johns Hopkins Hosp 95:1, 1954PubMedGoogle Scholar
  4. Sellers EM, Lang ML, Cooper SD, Koch-Weber J: Chloral hydrate and trichlofos metabolism. Clin Pharmacol Ther 14:147, 1973Google Scholar
  5. Seyffart G: Antihistamines and other sedatives. D. Chloral hydrate. In: Haddad LM and Winchester JF (eds): Clinical management of poisoning and drug overdose. Philadelphia: Saunders, 1990, chapter 46, p 835Google Scholar
  6. Stalker NE, Gambertoglio JG, Fukumitsu CJ, Naughton JL, Benet LZ: Acute massive chloral hydrate intoxication treated with hemodialysis: A clinical pharmacokinetic analysis. J Clin Pharmacol 18:136, 1978PubMedGoogle Scholar
  7. Vaziri ND, Kumar KP, Mirahmadi K, Rosen SM: Hemodialysis in treatment of acute chloral hydrate poisoning. South Med J 70:377, 1977PubMedCrossRefGoogle Scholar

Main references

  1. Adair CG, Bridges JM, Desai ZR: Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 17:99, 1986PubMedCrossRefGoogle Scholar
  2. Alberts DS, Chang SY, Chen HS, Larcom BJ, Jones SE: Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report. Cancer Treat Rev 6 (Suppl):9, 1979PubMedCrossRefGoogle Scholar
  3. McLean A, Woods RL, Catovsky D, Farmer P: Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treat Rev 6 (Suppl):33, 1979PubMedCrossRefGoogle Scholar
  4. Newell DR, Calvert AH, Harrap KR, McElwain TJ: Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol 15:253, 1983PubMedCrossRefGoogle Scholar

Main references

  1. Birrell DJ, Boyle PD, Craswell PW, Hunt FA: An epidemic of chloramine induced anaemia in a haemodialysis unit. Med J Aust 65(ll):288, 1978Google Scholar
  2. Botella J, Traver JA, Sanz-Guajardo D, Torres MT, Sanjuan I, Zabala P: Chloramines, an aggravating factor in the anaemia of patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 14:192, 1977PubMedGoogle Scholar
  3. Kjellstrand CM, Eaton JW, Yawata Y, Swofford H, Kolpin CF, Beselmeier TJ, von Hartitzsch B, Jacob HS: Hemolysis in dialyzed patients caused by chloramines. Nephron 13:427, 1974PubMedCrossRefGoogle Scholar
  4. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:955, chloramineGoogle Scholar

Main references

  1. Ambrose PJ: Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 9:222, 1984PubMedCrossRefGoogle Scholar
  2. Blouin RA, Erwin WG, Dutro MP, Bustrack JA, Rowse KL: Chloramphenicol hemodialysis clearance. Ther Drug Monit 2:351, 1980PubMedGoogle Scholar
  3. Grafnetterova J, Vodrazka Z, Jandova D, Schück O, Tomasek R, Lachmanova JL: The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency. Clin Nephrol 6:448, 1976PubMedGoogle Scholar
  4. Koup J, Lau A, Brodsky B, Slaughter R: Chloramphenicol pharmacokinetics in hospitalized patients. Antimicrob Agents Chemother 15:651, 1979PubMedCrossRefGoogle Scholar
  5. Kunin CM, Glazko AJ, Finland M: Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest 38:1498, 1959PubMedCrossRefGoogle Scholar
  6. Lindber AA, Nilsson LH, Bucht H: Concentration of chloramphenicol in the urine and blood in relation to renal function. Br Med J 2:724, 1966CrossRefGoogle Scholar
  7. Prat V, Grafnetterova J, Schück O, et al.: Comparison of renal excretion of chloramphenicol in patients with chronic pyelonephritis and polypeptic kidneys. Int J Clin Pharmacol Biopharm 13:71, 1976PubMedGoogle Scholar
  8. Slaughter RL, Cerra FB, Koup JR: Effect of hemodialysis on total body clearance of chloramphenicol. Am J Hosp Pharm 37:1083, 1980PubMedGoogle Scholar
  9. Suhrland LF, Weisberger AS: Chloramphenicol toxicity in liver and renal disease. Arch Intern Med 112:747, 1963PubMedCrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:477, chlorcyclizine dibunate.Google Scholar

Main references

  1. Breimer DD, Jochemsen R, Albert HH: Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneimittelforschung (Drug Res) 30(l):875, 1980Google Scholar
  2. Curry SH, Whelpton R: Pharmacokinetics of closely related benzodiazepines. Br J Clin Pharmacol 8:15S, 1979Google Scholar
  3. Greenblatt DJ, Shader Rl, MacLeod SM, Sellers EM: Clinical pharmacokinetics of chlordiazepoxide. Clin Pharmacokinet 3:381, 1978PubMedCrossRefGoogle Scholar
  4. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS: Benzodiazepines. A summary of pharmacokinetic properties. Br J Clin Pharmacol 11:11S, 1981Google Scholar

Main references Sclerosing peritonitis

  1. Buckle RG, Seabridge CE: The effect of Chlorhexidine in peritoneal cavity. Lancet 1963,I:193CrossRefGoogle Scholar
  2. Fabbri L, Grimaldi C, Zuchelli P: Peritonitis in CAPD: Treatment with Chlorhexidine. Dial & Transplant 11:483, 1982Google Scholar
  3. Junor BJR, Briggs JD, Forwell MA, Dobbie JW, Henderson J: Sclerosing peritonitis. The contribution of Chlorhexidine in alcohol. Perit Dial Bull 5:101, 1985Google Scholar
  4. Mackow RC, Winchester JF, Argy WP, Andrews PM, Fields PA, Bates S, Rakowski TA, Schreiner GE: Sclerosing encapsulating peritonitis in rats: An experimental study with intraperitoneal antiseptics. Contrib Nephrol 57:213, 1987PubMedGoogle Scholar
  5. Rottembourg J, Gahl GM, Poignet JL, Mertani E. Strippoli P, Langlois P, Tranbaloc P, Legrain M: Severe abdominal complications in patients undergoing continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Ass 20:236, 1983Google Scholar
  6. Shaldon S, Koch KM, Quellhorst E, Dinarello CA: Pathogenesis of sclerosing peritonitis in CAPD. Trans Am Soc Artif Intern Organs 30:193, 1984PubMedGoogle Scholar
  7. Slingeneyer A, Canaud B, Mourad G, Beraud JJ, Balmes M, Faller B, Mion C: Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 29:633, 1983PubMedGoogle Scholar
  8. Sobel JD, Hashman N, Reinherz G, Merzbach D: Nosocomial Pseudomonas cepacia infection associated with Chlorhexidine contamination. Am J Med 73:183, 1982PubMedCrossRefGoogle Scholar
  9. Sommerville PJ, Kaye M: Chlorhexidine is unsuitable for long-term use in patients on CAPD. Perit Dial Bull 4:195, 1982Google Scholar
  10. Suessmuth R, Ackermann B, Lingers F: Mutagenic effect of 1.1′-hexamethylene-bis[(5-p-chlorophenyl)-biguanide]. Chem Biol Interact 28:249, 1979PubMedCrossRefGoogle Scholar

Main reference

  1. Durwekar YG, Narula RK, Laumas KR: Distribution of α-3H-chlormadinone acetate in the reproductive tract of women. Contraception 7:313, 1973CrossRefGoogle Scholar

Main references

  1. Ali SL, Blume H: Determination of chlormezanone in human plasma after administration of chlormezanone formulations. Arzneimittelforschung (Drug Res) 37(II): 1396, 1987Google Scholar
  2. McChesney EW, Banks WF jr, Portmann GA, Crain AVR: Metabolism of chlormezanone in man and laboratory animals. Biochem Pharmacol 16:813, 1967PubMedCrossRefGoogle Scholar

Main references

  1. Akintonwa A, Odutola TA, Edeki T, Biola Mabadeje AF: Hemodialysis clearance of chloroquine in uremic patients. Ther Drug Monit 8:285, 1986PubMedCrossRefGoogle Scholar
  2. Barrett-Connor E: Drugs for the treatment of parasitic infection. Med Clin North Am 66:245, 1982PubMedGoogle Scholar
  3. Fabre J, DeFreudenrich J, Duchert A, Pitton JS, Rudhardt M, Virieux C: Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline. Helv Medice Acta 303:307, 1967Google Scholar
  4. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellstrom L, Jansson F: Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics. Clin Pharmacol Ther 25:345, 1979PubMedGoogle Scholar
  5. Mackenzie AH, Scherbel AL: Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 6:545, 1980Google Scholar
  6. Mackenzie AH: Pharmacologie actions of 4-aminoquinoline compounds. Am J Med 75 (Suppl. 1A, July):5, 1983PubMedCrossRefGoogle Scholar
  7. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:508, chloroquine.Google Scholar
  8. McChesney EW, Conway WD, Banks WF Jr. Rogers JE, Shek-osky JM: Studies of the metabolism of some compounds of the 4-amino-7-chloroquine series. J Pharmacol Exp Ther 15:482, 1966Google Scholar
  9. McChesney EW, Shekosky JM, Hernandez PH: Metabolism of chloroquine-3-14C in the rhesus monkey. Biochem Pharmacol 16:2444, 1967CrossRefGoogle Scholar
  10. Ritschel W, Hammer G, Thompson G: Pharmacokinetics of antimalarials and proposals for drug regimens. Int J Clin Pharmacol 16:395, 1978Google Scholar
  11. VanStone JC: Hemodialysis and chloroquine poisoning. J Lab Clin Med 88:87, 1976Google Scholar
  12. Zvaifler NJ, Rubin M, Berstein H: Chloroquine metabolism — drug excretion and tissue deposition. Arthritis Rheum 6:799, 1963Google Scholar

Main references

  1. Bricker NS: Sodium homeostasis in chronic renal disease. Kidney Int 21:868, 1982CrossRefGoogle Scholar
  2. Dreifus LS, Duarte CG, Kodama R, Moyer HJ: The effect of thiazide diuretics on the abnormal kidney. Ann Intern Med 53:1170, 1960PubMedGoogle Scholar
  3. Gerber JG: Antihypertensive agents and diuretics. In: Anderson RJ, Schrier RW (eds), Clinical use of drugs in patients with kidney and liver disease, London: Saunders, 1981 p 211Google Scholar
  4. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:981, chlorothiazideGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:959, chloroxylenol.Google Scholar

Main reference

  1. Forist AA, Judy RW: Comparative pharmacokinetics of chlorphenesin carbamate and methocarbamol in man. J Pharm Sci 60:1686, 1971PubMedCrossRefGoogle Scholar

Main references

  1. Chiou WL, Athanikar NA, Huang SM: Long half-life of chlorpheniramine. N Engl J Med 300:501, 1979PubMedGoogle Scholar
  2. Lai CM, Stoll RG, Look ZM; Yacobi A: Urinary excretion of chlorpheniramine and pseudoephedrine in humans. J Pharm Sci 68:1243, 1979PubMedCrossRefGoogle Scholar
  3. Patel JA, Phillips GL: A guide to physical combatibility of intravenous drug admixtures. Am J Hosp Pharm 23:409, 1966Google Scholar
  4. Peets EA, Jackson M, Symchowicz S: Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 180:464, 1972Google Scholar

Main reference

  1. Goenechea S, Rücker G, Brzezinka H, Hoffmann G, Neugebauer M, Pyzik T: Isolierung von Chlorphenoxamin-Metaboliten aus menschlischem Harn und ihre Identifizierung. Arzneimittelforschung (Drug Res) 37(II):854, 1987Google Scholar

Main references

  1. Dahl SG, Strandjord RE: Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437, 1977PubMedGoogle Scholar
  2. Loo JC, Midha KK, McGilveray IJ: Pharmacokinetics of chlorpromazine in normal volunteers. Commun Psychopharmacol 4:121, 1980PubMedGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:722, chlorpromazine.Google Scholar

Main references

  1. Arrigoni L, Fundak G, Horn J, Kradjan W, Ellsworth A, Opheim K, Taylor T, Bauer LA: Chlorpropamide pharmacokinetics in young healthy adults and older diabetic patients. Clin Pharm 6:162, 1987PubMedGoogle Scholar
  2. Graw RG, Clarke RR: Chlorpropamide intoxication — treatment with peritoneal dialysis. Pediatrics 45:106, 1970PubMedGoogle Scholar
  3. Petitpierre B, Perrin L, Rudhardt M, Herrera A, Fabre J: Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int J Clin Pharmacol 6:120, 1972PubMedGoogle Scholar
  4. Sharpstone P: Diseases of the urinary system. Prescribing for patients with renal failure. Br Med J 1977, 2:36PubMedCrossRefGoogle Scholar
  5. Taylor JA: Pharmacokinetics and biotransformation of chlorpropamide in man. Clin Pharmacol Ther 13:710, 1972PubMedGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:725, chlorprothixene.Google Scholar
  2. McAllister CJ, Scowden EB, Stone WJ: Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure. Clin Nephrol 10:191, 1978PubMedGoogle Scholar
  3. Raaflaub J: Zum Metabolismus des Chlorprothixen. Arzneimittelforschung (Drug Res) 17:1393, 1967Google Scholar
  4. Raaflaub J: On the pharmacokinetics of chlorprothixene in man. Experientia 31:557, 1975PubMedCrossRefGoogle Scholar

Main references

  1. Dieterle W, Wagner J, Faigle JW: Binding of chlorthalidone (Hygroton) to blood components in man. Eur J Clin Pharmacol 10:37. 1976CrossRefGoogle Scholar
  2. Fleuren HLJM, van Rossum JM: Pharmacokinetics of chlorthalidone in man. Pharm Weekbl (Sci) 110:1262, 1975Google Scholar
  3. Fleuren HLJM, Thein TA, Verwey-van Wissen CPW, van Rossum JM: Absolute bioavailability of chlorthalidone in man. A crossover study after intravenous and oral administration. Eur J Clin Pharmacol 15:35, 1979PubMedCrossRefGoogle Scholar
  4. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:983, chlorthalidone.Google Scholar
  5. Mulley BA, Parr GD, Rye RM: Pharmacokinetics of chlorthalidone. Dependence of biological half-life on blood carbonic anhydrase levels. Eur J Clin Pharmacol 17:203, 1980PubMedCrossRefGoogle Scholar
  6. Tweeddale MG, Ogilvie RI: Absorption and excretion of chlorthalidone (Hygroton) in man. Clin Res 20:913, 1972Google Scholar

Main reference

  1. Stewart JT, Chan CW: Fluorometric determination of chlorzoxazone in tablets and biological fluids J Pharm Sci 68:910, 1979PubMedCrossRefGoogle Scholar

Main references

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 1517, chapter 65, Agents affecting calcification: Calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds by RC Haynes jr and F MuradGoogle Scholar
  2. Henning HV, Fuchs C: Renale Osteopathie. Nieren- und Hochdruckkrankh 13:235, 1984Google Scholar
  3. Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29:98, 1986PubMedCrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th. ed. London: The Pharmaceutical Press, 1989:1197, cholestyramine.Google Scholar
  2. Silverberg DS, laina A, Reisin E, Rotzak R, Eliahou HE: Cholestyramine in uraemic pruritus. Br Med J 1977, 1:752PubMedCrossRefGoogle Scholar

Main reference

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1551, chapter 66, Water-soluble vitamins by R Marcus and AM CoulstonGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1258, cholineGoogle Scholar

Main references General

  1. Cohen A, Thomas GB, Cohen EB: Serum concentration, safety and tolerance of oral doses of choline magnesium trisalicy-late. Curr Ther Res 23:358, 1978Google Scholar

Main references Renal damage

  1. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984PubMedCrossRefGoogle Scholar
  2. Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985PubMedCrossRefGoogle Scholar
  3. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984PubMedCrossRefGoogle Scholar
  4. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980PubMedCrossRefGoogle Scholar
  5. Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984PubMedCrossRefGoogle Scholar
  6. Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987PubMedCrossRefGoogle Scholar
  7. Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982Google Scholar
  8. Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986CrossRefGoogle Scholar
  9. Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984PubMedCrossRefGoogle Scholar
  10. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980PubMedCrossRefGoogle Scholar
  11. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980PubMedCrossRefGoogle Scholar
  12. Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982PubMedGoogle Scholar
  13. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986PubMedCrossRefGoogle Scholar
  14. Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxi-zität. Dtsch Med Wochenschr 110:469, 1985PubMedCrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1144, chorionic gonadotropinGoogle Scholar
  2. Ross GT: Clinical relevance of research on the structure of human chorionic gonadotropin. Am J Obstet Gynecol 129:795, 1977PubMedGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:193, ciclacillinGoogle Scholar

Main references

  1. Gibson TP, Demetriades JL, Bland JA: Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med 78 (Suppl 6A): 54, 1985PubMedCrossRefGoogle Scholar
  2. Rogers JD, Meisinger MAP, Ferber F, Calandra GB, Demetriades JL, Bland JA: Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis 7 (Suppl 3):S435, 1985PubMedCrossRefGoogle Scholar
  3. Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME: The pharmacokinetics of imipenem (thienamy-cin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol 18:183, 1984PubMedCrossRefGoogle Scholar

Main references

  1. Bjaeldager PAL, Jensen JB, Larsen NE, Hvidberg EF: Elimination of oral Cimetidine in chronic renal failure and during haemo-dialysis. Br J Clin Pharmacol 9:585, 1980PubMedCrossRefGoogle Scholar
  2. Bjaeldager PAL, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF: Pharmacokinetics of Cimetidine in patients undergoing hemodialysis. Nephron 34:159, 1983PubMedCrossRefGoogle Scholar
  3. Burland WL, Duncan WAM, Hesselbo T, Mills JG, Sharpe PC, Haggie SJ, Wyllie JH: Pharmacological evaluation of Cimetidine. A new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol 2:481, 1975PubMedCrossRefGoogle Scholar
  4. Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F: Effect of Cimetidine on renal function in normal man. Clin Pharmacol Ther 24:76, 1978PubMedGoogle Scholar
  5. Finkelstein W, Isselbacher KJ: Cimetidine. N Engl J Med 299: 992, 1978PubMedCrossRefGoogle Scholar
  6. Hyneck ML, Murphy JF, Lipschutz DE: Cimetidine clearance during intermittent and chronic peritoneal dialysis. Am J Hosp Pharm 38:1760, 1981PubMedGoogle Scholar
  7. Jones RH, Lewin MR, Parsons V: Therapeutic effect of Cimetidine in patients undergoing haemodialysis. Br Med J 1:650, 1979PubMedCrossRefGoogle Scholar
  8. Kaye WA, Passero MA, Solomon RJ, Johnson LA: Cimetidine-induced interstitial nephritis with response to prednisone therapy. Arch Intern Med 143:811, 1983PubMedCrossRefGoogle Scholar
  9. Krichman KH, Cutler RE, Blair AD: Pharmacokinetics of Cimetidine in normal and uremic humans. W Soc Clin Pharmacol Ther 27:73A. AbstractGoogle Scholar
  10. Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L: Pharmacokinetics of Cimetidine and its sulphoxide metabolite during haemodialysis. Eur J Clin Pharmacol 21:325, 1982PubMedCrossRefGoogle Scholar
  11. Ma KW, Brown DC, Masler DS, Silvis SE: Effects of renal failure on blood levels of cimetidine. Gastroenterology 74:473, 1978PubMedGoogle Scholar
  12. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1082, Cimetidine.Google Scholar
  13. Pedersen PV, Miller R: Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 69:394, 1980PubMedCrossRefGoogle Scholar
  14. Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ: Removal of cimitidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. Ther Drug Monit 2:273, 1980PubMedCrossRefGoogle Scholar
  15. Randolph WC, Osborne VL, Walkenstein SS. Intoccia AP: High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-.receptor antagonist, in blood and urine. J. Pharm Sci 66:1148, 1977PubMedCrossRefGoogle Scholar
  16. Sawyer D, Conner CS, Scalley R: Cimetidine: Adverse reactions and acute toxicity. Am J Hosp Pharm 38:188, 1981PubMedGoogle Scholar
  17. Sedman AJ: Cimetidine-drug interactions. Am J Med 76:109, 1984PubMedCrossRefGoogle Scholar
  18. Somogyi A, Gugler R: Clinical pharmacokinetics of Cimetidine. Clin Pharmacokinet 8:463, 1983PubMedCrossRefGoogle Scholar
  19. Vaziri ND, Ness R, Barton CH: Hemodialysis clearance of Cimetidine. Arch Intern Med 138:1685, 1978PubMedCrossRefGoogle Scholar
  20. Vaziri ND, Ness RL, Barton CH: Peritoneal dialysis clearance of Cimetidine. Am J Gastroenterol 71:572, 1979PubMedGoogle Scholar

Main references

  1. Abranyi I: Therapeutische Erfahrungen mit Stugeron. Ther Hung 21:132, 1973Google Scholar
  2. Allewijn FTN: The distribution of cinnarizine and its metabolites in the rat. Life Sci 7 (Part l):989, 1968PubMedCrossRefGoogle Scholar
  3. Ellis F, Hyams DE, Jageneau AHM, Loots W: Vascular effects of cinnarizine in patients with intermittent claudication. J Int Med Res 3:93, 1975Google Scholar
  4. Soudijn W, van Wijngaarden I: The metabolism and excretion of cinnarizine by rats. Life Sci 7:231, 1968PubMedCrossRefGoogle Scholar
  5. Trumbull R, Chinn HI, Maag CH, Milch LJ, Handford SW, Seibert R, Sperling P, Smith PK: Effect of certain drugs on the incidence of seasickness. Clin Pharmacol Ther 1:280, 1960PubMedGoogle Scholar

Main references

  1. Brogard JM, Comte F, Lavillaureix J: Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. Eur J Drug Metab Pharmacokinet 8:251, 1983PubMedCrossRefGoogle Scholar
  2. Sisca TS, Heel RC, Romankiewics JA: Cinoxacin: A review of its pharmacological properties and therapeutics efficacy in the treatment of urinary tract infections. Drugs 25:544, 1983PubMedCrossRefGoogle Scholar
  3. Szwed JJ, Brannon DE, Sloan RS, Luft FC: Pharmacokinetics of cinoxacin in patients with renal failure. J Antimicrob Chemother 4:451, 1978PubMedCrossRefGoogle Scholar

Main references

  1. Aronoff GE, Kenner CH, Sloan RS, Pottratz ST: Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther 36:384, 1984PubMedCrossRefGoogle Scholar
  2. Bergan T, Thorsteinsson SB, Kolstad IM, Johnsen S: Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol 5:187, 1986PubMedCrossRefGoogle Scholar
  3. Bergan T, Dalhoff A, Rohwedder R: Pharmacokinetics of ciprofloxacin. Infection 16, Suppl 1:S3, 1988CrossRefGoogle Scholar
  4. Boelaert J, Valcke Y, Schurgers M, Daneels R, Rosseneu M, Rosseel MT, Bogaert MG: The pharmacokinetics of ciprofloxacin in patients with impaired renal function. J Antimicrob Chemother 16:87, 1985PubMedCrossRefGoogle Scholar
  5. Brogard JM, Jehl F, Monteil H, Adloff M, Blickle JF, Levy P: Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans. Antimicrob Agents Chemother 28:311, 1985PubMedCrossRefGoogle Scholar
  6. Crump B, Wise R, Dent J: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 24:784, 1983PubMedCrossRefGoogle Scholar
  7. Daschner FD, Westenfelder M, Dalhoff A: Penetration of ciprofloxacin into kidney fat, muscle and skin tissue. Eur J Clin Microbiol 5:212, 1986PubMedCrossRefGoogle Scholar
  8. Dharmasena D, Roberts DE, Coles GA, Williams JD: Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD. J Antimicrob Chemother 23:253, 1989PubMedCrossRefGoogle Scholar
  9. Golper TA, Hartstein AI, Morthland VH, Christensen JM: Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 31:1787, 1987PubMedCrossRefGoogle Scholar
  10. Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B: Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26:741, 1984PubMedCrossRefGoogle Scholar
  11. Höffken G, Lode H, Prinzing Z, Borner K, Koeppe P: Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27:375, 1985PubMedCrossRefGoogle Scholar
  12. Höffler D, Dalhoff A, Gan W, Beermann D, Michl A: Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol 3:363, 1984PubMedCrossRefGoogle Scholar
  13. Nix DE, De Vito JM: Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials. Clin Pharm 6:105, 1987PubMedGoogle Scholar
  14. Roberts DE, Williams JD: Ciprofloxacin in renal failure (leading article). J Antimicrob Chemother 23:820, 1989PubMedCrossRefGoogle Scholar
  15. Shalit I, Greenwood RB, Marks MI, Pederson JA, Frederick DL: Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrob Agents Chemother 30:152, 1986PubMedCrossRefGoogle Scholar
  16. Shalit I, Kitzes-Cohen R, Rapoport J, Schlaeffer F, Chaimovitz C: Pharmacokinetics of ciprofloxacin in patients receiving peritoneal dialysis and being treated for peritonitis. Rev Infect Dis 11, Suppl 5:14, 1989Google Scholar
  17. Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP: Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. Eur J Clin Pharmacol 31:589, 1987PubMedCrossRefGoogle Scholar
  18. Smith JT: Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J 233:299, 1984Google Scholar
  19. Staib AH, Beermann D, Harder S, Fuhr M, Liermann J: Differences of ciprofloxacin absorption along the gastrointestinal tract in man (Results of an HF-capsule-study). Naunyn Schmiedebergs Arch Pharmacol 338 (Suppl):R81, 1988Google Scholar
  20. Wingender W, Graefe KH, Gau W, Förster D, Beermann D, Schacht P: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 3:355, 1984PubMedCrossRefGoogle Scholar
  21. Zeiler HJ, Petersen U, Gau W, Ploschke HJ: Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Arzneimittelforschung (Drug Res) 37(I):131, 1987Google Scholar

Main references

  1. Bitran JD, Desser RK, Billing AA et al.: Acute nephrotoxicity following cis-dichlorodiammine platinum. Cancer 49:1784, 1982PubMedCrossRefGoogle Scholar
  2. Blachey JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628, 1981Google Scholar
  3. DeConti RC, Toftness BR, Lange RC, Creasey WA: Clinical and pharmacological studies with cis-diamminedichloroplatinum II. Cancer Res 33:1310, 1973PubMedGoogle Scholar
  4. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH: Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure. Cancer 41:1274, 1978PubMedCrossRefGoogle Scholar
  5. Einhorn LH, Williams SD: The role of cis-platinum in solid tumor therapy. N Engl J Med 300:289, 1979PubMedCrossRefGoogle Scholar
  6. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362, 1977CrossRefGoogle Scholar
  7. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sterberg SS: Acute renal failure after cis-dihlorodiammine platinum (II) and gentamicin-cephalotin therapies. Cancer Treat Rep 62:693, 1978PubMedGoogle Scholar
  8. Gormley PE, Bull JM, LeRoy AF, Cysyk R: Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25:351, 1979PubMedGoogle Scholar
  9. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH: High-dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372, 1977PubMedCrossRefGoogle Scholar
  10. Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65:307, 1978PubMedCrossRefGoogle Scholar
  11. Prestayko AW, Luft FC, Einhorn L, Crooke ST: Cis-platinum pharmacokinetics in a patient with renal dysfunction. Med Pediatr Oncol 5:183, 1978PubMedCrossRefGoogle Scholar
  12. Schilsky RL, Howell SB: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929, 1979PubMedGoogle Scholar
  13. Stark JJ, Howell SB: Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 23:461, 1978PubMedGoogle Scholar
  14. Ward JM, Grabin ME, Berlin E, Young DM: Prevention of renal failure in rats receiving cis-diammine dichloroplatinum (II) by administration of furosemide. Cancer Res 37:1238, 1977PubMedGoogle Scholar

Main references

  1. Bodey GP, Yeo E, Ho DH, Rolston K, LeBlanc B: Clinical pharmacology of timentin (ticarcillin and clavulanic acid). Clin Pharmacol Ther 37:134, 1985CrossRefGoogle Scholar
  2. Horber FF, Frey FJ, Descoeudres C, Murray AT, Reubi FC: Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Antimicrob Agents Chemother 29:614, 1986PubMedCrossRefGoogle Scholar
  3. Jackson D, Cooper DL, Filer CW, Langley PF: Augmentin, absorption, excretion and pharmacokinetic studies in man. Postgrad Med 76 (Suppl):51, 1984Google Scholar
  4. Koeppe P, Höffler D, Hulla FW: Pharmacokinetic studies on clavulanate potentiated ticarcillin in normal subjects and patients with renal insufficiency. Arzneimittelforschung (Drug Res) 37:203, 1987Google Scholar
  5. Slaughter RL, Kohli R, Brass C: Effects of hemodialysis on the pharmacokinetics of amoxicillin/clavulanic acid combination. Ther Drug Monit 6:424, 1984PubMedCrossRefGoogle Scholar

Main references

  1. Sandoz (Basel, Switzerland): Dokumentation Tavegil (1984)Google Scholar
  2. Tham R, Norlander B, Hägermark Ö, Fransson L: Gaschromatography of clemastine. A study of plasma kinetics and biological effect. Arzneimittelforschung (Drug Res) 280(I):1017, 1978Google Scholar

Main references

  1. Offerhaus L: Clenbuterol: het ‘herverdelingsmiddel’. Ned Tijdschr Geneeskd 132:1782, 1988PubMedGoogle Scholar
  2. Yamamoto I, Iwata K, Nakashima M: Pharmacokinetics of plasma and urine clenbuterol in man, rat and rabbit. J Pharmacobiodyn 8:385, 1985PubMedCrossRefGoogle Scholar
  3. Zimmer A: Einmalapplikation, Mehrfachapplikation und Metabolitenmuster von Clenbuterol beim Menschen. Arzneimittelforschung (Drug Res) 26:1446, 1976Google Scholar

Main references

  1. Brandl R, Arkenau C, Simon C, Malerczyk V, Eidelloth G: Zur Pharmakokinetik von Clindamycin bei gestörter Leber- und Nierenfunktion. Dtsch Med Wochenschr 97:1057, 1972PubMedCrossRefGoogle Scholar
  2. Cimino JE, Tierno PM jr: Hemodialysis of clindamycin (7-chloro-7-deoxylincomycin). Appl Microbiol 17:446, 1969PubMedGoogle Scholar
  3. DeHaan RM, Metzler CM, Schellenberg D, et al.: Pharmacokinetic studies of clindamycin hydrochloride in humans. Int J Clin Pharmacol 6:105, 1972PubMedGoogle Scholar
  4. Eastwood JB, Gower PE: A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure. Postgrad Med J 50:719, 1974CrossRefGoogle Scholar
  5. Fass RJ, Saslaw S: Clindamycin: Clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 263:369, 1972CrossRefGoogle Scholar
  6. Golper TA, Sewell DL, Fisher PB, Wolfson M: Incomplete activation of intraperitoneal clindamycin phosphate during peritoneal dialysis. Am J Nephrol 4:38, 1984PubMedCrossRefGoogle Scholar
  7. Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR: Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur J Clin Pharmacol 14:435, 1978PubMedCrossRefGoogle Scholar

Main references

  1. Berggren L, Hansson O: Absorption of intestinal antiseptics derived from 8-hydroxyquinolines. Clin Pharmacol Ther 9:67, 1968PubMedGoogle Scholar
  2. Jack DB, Riess W: Pharmacokinetics of iodochlorhydroxyquin in man. J Pharm Sci 62:1929, 1973PubMedCrossRefGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press. 1989:661. clioquinol.Google Scholar

Main references

  1. Brogden RN, Heel RC, Speight TM, Avery GS: Clobazam: A review of its pharmacological properties and therapeutic use in anxiety. Drugs 20:161, 1980PubMedCrossRefGoogle Scholar
  2. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI: Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8:233, 1983PubMedCrossRefGoogle Scholar

Main references General

  1. Thuillier J, Bessin P, Geffroy F, Godfroid JJ: Chimie et pharmacoligie de la Clofezone. Bull Chimie Therapeutique 1968, No 1:53Google Scholar

Main references Renal damage

  1. Abraham PA, Keane WF: Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 4:1, 1984PubMedCrossRefGoogle Scholar
  2. Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992, 1985PubMedCrossRefGoogle Scholar
  3. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 310:563, 1984PubMedCrossRefGoogle Scholar
  4. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 18:553, 1980PubMedCrossRefGoogle Scholar
  5. Dunn MJ: Non-steroidal anti-inflammatory drugs and renal function. Annu Rev Med 35:411, 1984PubMedCrossRefGoogle Scholar
  6. Hart D, Lifschitz MD: Renal physiology of the prostaglandins and the effects of nonsteroidal anti-inflammatory agents on the kidney. Am J Nephrol 7:408, 1987PubMedCrossRefGoogle Scholar
  7. Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2:478, 1982Google Scholar
  8. Orme ML’E: Non-steroidal anti-inflammatory drugs and the kidney. Br Med J 292:1521, 1986CrossRefGoogle Scholar
  9. Reeves WB, Foley RJ, Weinman EJ: Renal dysfunction from nonsteroidal anti-inflammatory drugs. Arch Intern Med 144:1943, 1984PubMedCrossRefGoogle Scholar
  10. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (First of two parts). N Engl J Med 302:1179, 1980PubMedCrossRefGoogle Scholar
  11. Simon LS, Mills JA: Nonsteroidal antiinflammatory drugs (Second of two parts). N Engl J Med 302:1237, 1980PubMedCrossRefGoogle Scholar
  12. Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 57:389, 1982PubMedGoogle Scholar
  13. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DG: Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney Int 30:760, 1986PubMedCrossRefGoogle Scholar
  14. Wegmüller E: Nicht-steroidale Antirheumatika und Nephrotoxizität. Dtsch Med Wochenschr 110:469, 1985PubMedCrossRefGoogle Scholar

Main references

  1. Bridgman JF, Rosen SM, Thorp JM: Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. Lancet II:506, 1972CrossRefGoogle Scholar
  2. DiGiulio S, Boulu R, Drueke T et al.: Clofibrate treatment of hyperlipidemia in chronic renal failure. Clin Nephrol 8:504, 1977Google Scholar
  3. Faed EM, McQueen EG: Plasma half-life of clofibric acid in renal failure. Br J Clin Pharmacol 7:407, 1979PubMedCrossRefGoogle Scholar
  4. Gokal R, Mann JI, Oliver DO, Ledingham JGG, Carter RD: Treatment of hyperlipidaemia in patients on chronic haemodialysis. Br Med J 1:82, 1978PubMedCrossRefGoogle Scholar
  5. Goldberg AP, Sherrard DJ, Haas LB, Brunzell JD: Control of clofibrate toxicity in uremic hypertriglyceridemia. Clin Pharmacol Ther 21:317, 1977PubMedGoogle Scholar
  6. Gugler R: Clinical pharmacokinetics of hypolipidaemic drugs. Clin Pharmacokinet 3:425, 1978PubMedCrossRefGoogle Scholar
  7. Harvengt C, Desager JP: Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol Biopharm 15:1, 1977PubMedGoogle Scholar
  8. Merk W, Graben N, Hartmann H, Nikolaus C, Schliert G, Schwandt P: Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees — a multicenter study. Int J Clin Pharmacol Ther Toxicol 25:59, 1987PubMedGoogle Scholar
  9. Moses AM, Howanitz J, Van Gemert M et al.: Clofibrate-induced antidiuresis. J Clin Invest 52:535, 1977CrossRefGoogle Scholar
  10. Pierides AM, Alvarez-Ude F, Kerr DNS: Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet II:1279, 1975.CrossRefGoogle Scholar
  11. Sherrard DJ, Goldberg AD, Haas LB, Brunzell JD: Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron 25:219, 1980PubMedCrossRefGoogle Scholar
  12. Viikari J, Anttila M, Kasanen A: The use of clofibrate in patients with renal insufficiency. Int J Clin Pharmacol Ther Toxicol 21:77, 1983PubMedGoogle Scholar

Main references

  1. Harvengt C, Desager JP: Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorphenoxyisobutyric acid (CPIB) in volunteers. Int J Clin Pharmacol Biopharm 14:113, 1976PubMedGoogle Scholar
  2. Harvengt C, Desager JP: Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol Biopharm 15:1, 1977PubMedGoogle Scholar

Main references

  1. Ende M, Spiteller G, Remberg G, Heipertz R: Urinary metabolites of clomethiazole. Detection and structural analysis by gas chromatography-mass spectrometry. Arzneimittelforsch (Drug Res) 29(II):1655, 1979Google Scholar
  2. Fischler M, Frisch EP, Ortengren P: Plasma concentrations after oral administration of different pharmaceutical preparations of clomethiazole. Acta Pharm Suec 10:483, 1973PubMedGoogle Scholar
  3. Moore RG, Triggs EJ, Shanks CA, Thomas J: Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 8:353, 1975PubMedCrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1394, clomiphene citrate.Google Scholar

Main references

  1. Faigle JW, Dieterle W: The metabolism and pharmacokinetics of clomipramine (Anafranil). J Int Med Res 1:281, 1973Google Scholar
  2. Jones RB, Tech B, Luscombe DK: Plasma levels studies with clomipramine (Anafranil). J Int Med Res 5 (Suppl 1):98, 1977PubMedGoogle Scholar
  3. Luscombe DK: Pharmacokinetics of clomipramine. Br J Clin Pract 33 (Suppl 3):35, 1979Google Scholar
  4. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:358, clomipramine hydrochloride.Google Scholar
  5. Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK: Hydroxylated metabolites of tricyclic antidepressants: Preclinical assessment of activity. Biol Psychiatry 14:601, 1979PubMedGoogle Scholar

Main references

  1. Klotz U, Kangas L, Kants J: Clinical pharmacokinetics of benzodiazepines. Prog in pharmacol vol. 3, Stuttgart: G. Fischer Verlag, 1980Google Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:402, clonazepam.Google Scholar

Main references

  1. Frisk-Holmberg M, Paalzow L, Edlund PO: Clonidine kinetics in man — evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol 12:653, 1981PubMedCrossRefGoogle Scholar
  2. Houston MC: Clonidine hydrochloride: Review of pharmacologic and clinical aspects. Prog Cardiovasc Dis 23:337, 1981PubMedCrossRefGoogle Scholar
  3. Hulter HN, Licht JH, Ilnicki LP, Singh S: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency. J Lab Clin Med 94:223, 1979PubMedGoogle Scholar
  4. Lowenstein J: Drugs five years later: Clonidine. Ann Intern Med 92:74, 1980PubMedGoogle Scholar
  5. Lowenthal DT, Affrime MB, Meyer A, Kim KE, Falkner B, Sharif K: Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function. Chest 83 (Febr. Suppl 2):386, 1983PubMedCrossRefGoogle Scholar
  6. Mirkin BL, Green TP, O’Dea RF: Disposition and pharmacodynamics of diuretics and antihypertensive agents in renal disease. Eur J Clin Pharmacol 18:109, 1980PubMedCrossRefGoogle Scholar

Main references

  1. Bricker NS: Sodium homeostasis in chronic renal disease. Kidney Int 21:868, 1982CrossRefGoogle Scholar
  2. Dreifus LS, Duarte CG, Kodama R, Moyer HJ: The effect of thiazide diuretics on the abnormal kidney. Ann Intern Med 53:1170, 1960PubMedGoogle Scholar
  3. Gerber JG: Antihypertensive agents and diuretics. In: Anderson RJ, Schrier RW (eds). Clinical use of drugs in patients with kidney and liver disease, London: Saunders, 1981 p 211Google Scholar

Main references

  1. Ochs HR, Steinhaus E, Locniskar A, Knüchel M, Greenblatt DJ: Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. Klin Wochenschr 60:411, 1982PubMedCrossRefGoogle Scholar
  2. Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ: Clorazepate dipotassium and diazepam in renal insufficiency: Serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 37:100. 1984PubMedCrossRefGoogle Scholar

Main references

  1. Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H: Disposition of clotiazepam: Influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol 26:55, 1984PubMedCrossRefGoogle Scholar

Main references

  1. Duhm B, Maul W, Medenwald H, Patzschke H, Pütter J, Wegner LA: The pharmacokinetics of clotrimazole 14C. Postgrad Med J 50 (Suppl 1): 13, 1974PubMedGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:421, clotrimazole.Google Scholar
  3. Menz HP, Teltscher U, Bayer C, v Oldershausen HF: Zur Pharmakokinetik des oralen Antimykotikums Clotrimazol beim Menschen. Dtsch Med Wochenschr 98:1606, 1973PubMedCrossRefGoogle Scholar
  4. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R: Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 144:290, 1984PubMedCrossRefGoogle Scholar
  5. Plempel M, Bartmann K, Büchel H, Regel E: Experimentelle Befunde über ein neues, oral wirksames Antimykotikum mit breitem Wirkungsspektrum. Dtsch Med Wochenschr 94:1356, 1969PubMedCrossRefGoogle Scholar
  6. Rozenkranz H, Pütter J: The binding of clotrimazole to the proteins of human serum. Eur J Drug Metab Pharmacokinet 1:73, 1976CrossRefGoogle Scholar
  7. Weuta H: Klinische Erfahrungen mit der systemischen Verabreichung von Clotrimazol: Pharmakokinetik, Wirkung, Verträglichkeit. Arzneimittelforschung (Drug Res) 24:540, 1974Google Scholar

Main reference

  1. Nauta EH, Mattic H: Pharmacokinetics of flucloxacillin and doxacillin in healthy subjects and patients on chronic intermittent hemodialysis. Br J Clin Pharmacol 2:111, 1975PubMedCrossRefGoogle Scholar

Main references

  1. Court-Brown CM: The effect of external skeletal fixation on bone healing and bone blood supply. Clin Orthop 201:278, 1985PubMedGoogle Scholar
  2. Ford K, Harris CC, Coleman RE, Dunnick NR: The radionuclide renogram as a predictor of relative renal blood flow. Radiology 149:819, 1983PubMedGoogle Scholar
  3. Selman J (ed): Fundamentals of X-ray and radium physics, (6th ed.) Springfield, II.: Charles Thomas, 1977 p 495Google Scholar
  4. Selman J (ed): Fundamentals of X-ray and radium physics, (6th ed.) Springfield, II.: Charles Thomas, 1977 p 505Google Scholar

Main references

  1. Caldwell J, Sever PS: The biochemical pharmacology of abused drugs. I. Amphetamines, cocaine and LSD. Clin Pharmacol Ther 16:625, 1974PubMedGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1213, cocaine.Google Scholar
  3. Tucker GT, Mather LE: Properties, absorption, and disposition of local anesthetic agents. In: Cousins MJ (ed): Neural blockade in clinical anesthesia and management of pain, 2nd ed., Philadelphia: JB Lippincott, 1988 p 47Google Scholar

Main references

  1. Bechtel WD, Sinterhauf K: Plasma level and renal excretion of (3H) codeine phosphate in man and in the dog. Arzneimittelforschung (Drug Res) 28(I):308, 1978Google Scholar
  2. Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies on the metabolic N- and O-demethylation of (6-3H)codeine. Drug Metab Dispos 11:477, 1983PubMedGoogle Scholar
  3. Guay DRP, Matzke GR, Findlay JWA, Halstenson CE, Awni WM, Opsahl JA, Abraham PA: Codeine pharmacokinetics (PK) and pharmacodynamics (PD) in hemodialysis (HD) patients. Clin Pharmacol Ther 41:222, 1987Google Scholar
  4. Levine DF: Hypocalcaemia increases the narcotic effect of codeine. Postgrad Med J 56:736, 1980PubMedCrossRefGoogle Scholar
  5. Matzke GR, Chan GLC, Abraham PA: Codeine dosage in renal failure. Clin Pharm 5:15, 1986PubMedGoogle Scholar
  6. Ritschel WA: Pharmacokinetic aspects of analgesics. Methods Find Exp Clin Pharmacol 4:479, 1982PubMedGoogle Scholar
  7. Vaughan DP, Beckett AH: The influence of reducing the C7-C8 double bond of codeine to give dihydrocodeine on the relative physiological availability of the drugs in man. J Pharm Pharmacol 25 (Suppl.): 104P, 1973Google Scholar
  8. Way EL, Adler TK: The biological disposition of morphine and its surrogates. 2. Bull WHO 26:51, 1962PubMedGoogle Scholar

Main references

  1. Carr AA: Colchicine toxicity. Arch Intern Med 115:29, 1965PubMedCrossRefGoogle Scholar
  2. Cheigh JS: Drug administration in renal failure. Am J Med 62:555, 1977PubMedCrossRefGoogle Scholar
  3. Donigian DW, Owellen RJ: Interaction of vinblastine, vincristine and colchicine with serum proteins. Biochem Pharmacol 22:2113, 1973PubMedCrossRefGoogle Scholar
  4. Ellwood MG, Robb GH: Self-poisoning with colchicine. Postgrad Med J 47:129, 1971PubMedCrossRefGoogle Scholar
  5. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:674, chapter 29, Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout by RJ Flower, D Moncada and JR VaneGoogle Scholar
  6. Knepshield JH, Schreiner GE, Lowenthal DT, Gelfand MC: Dialysis of poisons and drugs — annual review. Trans Am Soc Artif Intern Organs 19:590, 1973PubMedCrossRefGoogle Scholar
  7. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M: Colchicine myopathy and neuropathy. N Engl J Med 316:1562, 1987PubMedCrossRefGoogle Scholar
  8. Wallace SI, Omokoku B, Ertel NH: Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am J Med 48:443, 1970PubMedCrossRefGoogle Scholar

Main reference

  1. Düntsch G: Colestipol bei Hypercholesterinämie bei Diabetikern. Fortschr Med 95:1492, 1977PubMedGoogle Scholar

Main references

  1. Adler S, Segel DP: Nonoliguric renal failure secondary to sodium colistimethate: A report of four cases. Am J Med Sci 262:109, 1971PubMedCrossRefGoogle Scholar
  2. Brown JM, Dorman DC, Roy LP: Acute renal failure due to overdosage of Colistin. Med J Aust 2:923, 1970PubMedGoogle Scholar
  3. Curtis JR, Eastwood JB: Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and oeritoneal dialysis. Br Med J 1:484, 1968CrossRefGoogle Scholar
  4. Froman J, Gross L, Curatola S: Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 103:210, 1970PubMedGoogle Scholar
  5. Gibaldi M, Perrier D: Drug distribution and renal failure. J Clin Pharmacol 12:201, 1972Google Scholar
  6. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1170, chapter 52, Antimicrobial agents by MA Sande and GL MandellGoogle Scholar
  7. Goodwin NJ, Friedman EA: The effect of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med 68:984, 1968PubMedGoogle Scholar
  8. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE: Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72:857, 1970PubMedGoogle Scholar
  9. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:204, Colistin sulphateGoogle Scholar
  10. Price DJE, Graham Dl: Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 4:525, 1970PubMedCrossRefGoogle Scholar
  11. Sharpstone P: Diseases of the urinary system. Prescribing for patients with renal failure. Br Med J 2:36, 1977PubMedCrossRefGoogle Scholar
  12. Swick HM, Maxwell E, Charache P, Levin S: Peritoneal dialysis in colistin intoxication: Report of a case. J Pediatr 74:976, 1969PubMedCrossRefGoogle Scholar
  13. Vinnicombe J, Stamey TA: The relative nephrotoxicities of polymyxin B sulfate, sodium sulfomethyl-polymyxin B, sodium sulfomethyl-colistin (Colymycin), and neomycin sulfate. Invest Urol 6:505, 1969PubMedGoogle Scholar
  14. Wolinsky E, Hines JD: Neurotoxic and nephrotoxic effects of Colistin in patients with renal disease. N Engl J Med 266:759, 1962PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1139, corticotrophinGoogle Scholar

Main references

  1. Asbach HW, Vecsei P, Schüler HW, Gless KH: Serum- und Dialysatspiegel von Corticosteroiden bei Langzeit-Hämodialyse. Dtsch Med Wochenschr 98:1758, 1973PubMedCrossRefGoogle Scholar
  2. Bacon GF, Kenny FM, Murdaugh HV, Richards C: Prolonged serum half-life of Cortisol in renal failure. Johns Hopkins Med J 132:127, 1973PubMedGoogle Scholar
  3. Deck KA: Das Verhalten der 11-Hydroxycorticoide im Plasma während der extracorporalen Hämodialyse. Klin Wochenschr 45:1006, 1967PubMedCrossRefGoogle Scholar
  4. Knapp E, Staudinger E, Dittrich P: Das Verhalten des freien Plasmacortisols während extracorporaler Hämodialyse. Klin Wochenschr 48:1243, 1970PubMedCrossRefGoogle Scholar
  5. Peterson RE, Pierce CE, Wyngaarden JB, Bunim JJ, Brodie BB: The physiological disposition and metabolic fate of cortisone in man. J Clin Invest 36:1301, 1957PubMedCrossRefGoogle Scholar

Main references

  1. Andreasen F, Elsborg L, Husted S, Thomsen O: Pharmacokinetics of sulfadiazine and trimethoprim in man. Eur J Clin Pharmacol 14:57, 1978PubMedCrossRefGoogle Scholar
  2. Appel GB, Neu HC: The nephrotoxicity of antimicrobial agents (First of three parts). N Engl J Med 296:663, 1977PubMedCrossRefGoogle Scholar
  3. Goldsmith HJ, Makamoto S, Kolff WJ: Expanding the indications for treatment with the artificial kidney. Burns, cerebral oedema, sulphonamide intoxication, and congestive heartfailure. Lancet 11:111, 1960CrossRefGoogle Scholar
  4. Leone N, Barzaghi N, Monteleone M, Perucca E, Cerutti R, Crema A: Pharmacokinetics of co-trimazine after single and multiple doses. Arzneimittelforschung (Drug Res) 37(I): 70, 1987Google Scholar

Main references

  1. Bourgault AM, Van Scoy RE, Brewer NS, Rosenow EC: Trimethoprim with sulfamethoxazole for treatment of infection with Pneumocystis carinii in renal insufficiency. Chest 74:91, 1978PubMedCrossRefGoogle Scholar
  2. Caterson RJ, Collett PV, Hood VL, Duggin GG, Horvath JS, Johnson JR, Sampson J, Tiller DJ: Trimethoprim/sulfamethoxazole and renal function in transplant patients. Clin Pharmacol Ther 23:553, 1978PubMedGoogle Scholar
  3. Günther K, Traeger A, Stein G: Pharmakokinetik der Sulfonamid-Trimethoprim-Kombinationen Berlocombin und Sulprim bei Patienten mit verschiedenen Graden einer Nierenfunktionseinschränkung. Pharmazie 39:250, 1984PubMedGoogle Scholar
  4. Halstenson CE, Blevins RB, Salem NG, Matzke GR: Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin Nephrol 22:239, 1984PubMedGoogle Scholar
  5. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:206, co-trimoxazoleGoogle Scholar
  6. Patel RB, Welling PG: Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet 5:405, 1980PubMedCrossRefGoogle Scholar
  7. Richmond JM, Whitworth JA, Fairley KF, Kincaid-Smith P: Co-trimoxazole nephrotoxicity. Lancet 1:493, 1979PubMedCrossRefGoogle Scholar
  8. Rieder J, Schwartz DE, Fernex M, Bergan T, Brodwall EK, Blumberg A, Cottier P, Scheitlin W: Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot Chemother 18:148, 1974PubMedGoogle Scholar
  9. Shouval D, Ligumsky M, Ben-Ishay D: Effect of co-trimoxazole on normal creatinine clearance. Lancet 1:224, 1978Google Scholar
  10. Siber GR, Gorham CC, Ericson JF, Smith AL: Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis 4:566, 1982PubMedCrossRefGoogle Scholar
  11. Singlas E, Colin JN, Rottembourg J, Meessen JP, de Martin A, Legrain M, Simon P: Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: Effect of peritonitis. Eur J Clin Pharmacol 21:409, 1982PubMedCrossRefGoogle Scholar
  12. Tasker PRW, MacGregor GA, de Wardener HE, Thomas RD, Jones NF: Use of co-trimoxazole in chronic renal failure. Lancet 1:1216, 1975PubMedCrossRefGoogle Scholar
  13. Watson ID, Stewart MJ, Wiles A, McIntosh SJ: Pharmacokinetics of two dosage levels of trimethoprim to ‘steady-state’ in normal volunteers. J Int Med Res 11:137, 1983PubMedGoogle Scholar

Main references

  1. Bastow MD, Woods HF, Walls J: Persistent anemia associated with reduced serum vitamin B12 levels in patients undergoing regular hemodialysis therapy. Clin Nephrol 11:133, 1979PubMedGoogle Scholar
  2. Chanarin I, Hutchinson M, McLean A, Moule M: Hepatic folate in man. Br Med J 1:396, 1966PubMedCrossRefGoogle Scholar
  3. Cooper BA: Megaloblastic anaemia and disorders affecting utilisation of vitamin B12 and folate in childhood. Clin Haematol 5:631, 1976PubMedGoogle Scholar
  4. Hakami N, Neiman PE, Canellos GP, Lazerson J: Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med 285:1163, 1971PubMedCrossRefGoogle Scholar
  5. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1260, cyanocobalaminGoogle Scholar
  6. Matthews DM, Beckett AG: Serum vitamin B12 in renal failure. J Clin Pathol 15:456, 1962PubMedCrossRefGoogle Scholar
  7. Reizenstein P, Ek G, Matthews CM: Vitamin B12 kinetics in man. Implications on total-body-B12 determinations, human requirements, and normal and pathological cellular B12 uptake. Phys Med Biol 11:295, 1966PubMedCrossRefGoogle Scholar
  8. Rosner F, Schreiber ZA: Serum vitamin B12 and vitamin B12 binding capacity in chronic myelogenous leukemia and other disorders. Am J Med Sci 263:473, 1972PubMedCrossRefGoogle Scholar
  9. Sevitt LH, Hoffbrand AV: Serum folate and vitamin B12 levels in acute and chronic renal disease. Effect of peritoneal dialysis. Br Med J 1969. 2:18PubMedCrossRefGoogle Scholar
  10. Stein G, Sperschneider H, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3:52, 1985PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1495, cyclandelateGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:450 cyclizineGoogle Scholar

Main references

  1. Breimer DD, Winten MACM: Pharmacokinetics and relative bioavailability of cyclobarbital calcium in man after oral administration. Eur J Clin Pharmacol 9:443, 1976CrossRefGoogle Scholar
  2. Goldbaum LR, Smith PK: The binding of barbiturates by human and bovine serum albumin. Federation Proc 7:222, 1948Google Scholar
  3. Kennedy AC, Lindsay EM, Briggs JD, Luke RG, Young N, Campbell D: Successful treatment of three cases of very severe barbiturate poisoning. Lancet 1:995, 1969PubMedCrossRefGoogle Scholar

Main reference

  1. Hucker HB, Stauffer SC, Albert KS, Lei BW: Plasma levels and bioavailability of cyclobenzaprine in human subjects. J Clin Pharmacol 17:719, 1977PubMedGoogle Scholar

Main reference

  1. Mishima S: Clinical Pharmacokinetics of the eye. Proctor lecture. Invest Ophthal Vis Sci 21:504, 1981PubMedGoogle Scholar

Main references

  1. Bagley CM, Bostick FW, DeVita VT: Clinical pharmacology of cyclophosphamide. Cancer Res 33:226, 1973PubMedGoogle Scholar
  2. Bending MR, Finch RE: Hemodialysis during cyclophosphamide treatment. Br Med J 1:1145, 1978PubMedCrossRefGoogle Scholar
  3. Cheig JS, Reidenberg MM: Cyclophosphamide dose in renal failure. Am J Med 64:725, 1978Google Scholar
  4. DeFronzo RA, Colvin OM, Braine H, Robertson GL, Davis PJ: Cyclophosphamide and the kidney. Cancer 33:483, 1974PubMedCrossRefGoogle Scholar
  5. D’Incalci M, Bolis G, Facchinetti T, Mangioni C, Morasca L, Morazzoni P, Salmona M: Decreased half-life of cyclophosphamide in patients under continual treatment. Eur J Cancer 15:7, 1979PubMedCrossRefGoogle Scholar
  6. DeVita VT, Adamson RH: Metabolism of 14C-cyclophosphamide. Prog Antimicrob Anticancer Chemother 2:218, 1970Google Scholar
  7. Grochow LB, Colvin M: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4:380, 1979PubMedCrossRefGoogle Scholar
  8. Humphrey RL, Kvols RK: The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery. Proc Am Assoc Cancer Res 15:84, 1974Google Scholar
  9. Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19:443, 1981PubMedCrossRefGoogle Scholar
  10. Kroener J, Green M: Cyclophosphamide dose in renal failure (Letter). Am J Med 64:725, 1978PubMedCrossRefGoogle Scholar
  11. Lopes VM: Cyclophosphamide nephrotoxicity in man. Lancet I:1060, 1967CrossRefGoogle Scholar
  12. Marbury TC, Wang LH, Lee CS, Majeske BL: Hemodialyzability of cyclophosphamide. Kidney Int 19:154, 1981Google Scholar
  13. Milsted RAV, Jarman M: Haemodialysis during cyclophosphamide treatment. Br Med J 1:820, 1978PubMedCrossRefGoogle Scholar
  14. Mouridsen HT, Jacobsen E: Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol (Copenh) 36:409, 1975CrossRefGoogle Scholar
  15. Wagner T, Heydrick D, Bartels H, Hohorst HJ: Einfluß von Leberparenchymschäden, Niereninsuffizienz und Hämodialyse auf die Pharmakokinetik von Cyclophosphamid und seinen aktiven Metaboliten. Arzneimittelforschung (Drug Res) 30:1588, 1980Google Scholar
  16. Wang LH, Lee CS, Majeske BL, Marbury TC: Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cell, and dialysat measurements for cyclophosphamide. Clin Pharmacol Ther 29:365, 1981PubMedCrossRefGoogle Scholar

Main references

  1. Goodman and Gilman’s The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:1115, chapter 50, Antimicrobial agents by GL Mandell and MA Sande.Google Scholar
  2. Kucers A, Mck.Bennett N (eds). The use of antibiotics, 3rd ed. London: Heinemann, 1979 p 457Google Scholar
  3. Otten H, Plempel M, Siegenthaler W. (eds.) Antibiotika-Fibel: Sulfonamide. 4th ed. Stuttgart: Georg Thieme, 1975 p 583Google Scholar
  4. Reed MD, Blumer JL: Clinical pharmacology of antitubercular drugs. Pediatr Clin North Am 30:177, 1983PubMedGoogle Scholar

Main references

  1. Bozkurt E, Stierle H, Schollmeyer P, Keller E: Single-dose response kinetics of cyclosporine. Clin Nephrol 28:10, 1987PubMedGoogle Scholar
  2. Fullath F, Wenk M, Vozeh S et al.: Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34:638, 1983CrossRefGoogle Scholar
  3. Impact of cyclosporine in medicine. Transplant Proc 20 (Suppl 2):3, 1988Google Scholar
  4. Kahan BD: Cyclosporine nature of the agent and its immunologic actions. New York: Harcourt Brace Javanovich, 1988Google Scholar
  5. Keller F, Walz G, Kunzendorf U, Haller H, Kramer W, Schwarz A, Offermann G: Initiale Pharmakokinetik und langfristiger Dosisbedarf von Cyclosporin. Nieren- und Hochdruckkrankh 16:294, 1987Google Scholar
  6. Leithner C, Ulrich W, Schwarz M: Die Nephrotoxizität von Cyclosporin A. Nieren- und Hochdruckkrankh 15:529, 1986Google Scholar
  7. Martindale The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:614, cyclosporin AGoogle Scholar
  8. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699, 1984PubMedCrossRefGoogle Scholar
  9. Ptachcinski RJ, Venkataramanan R, Burckart GJ: Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11:107, 1986PubMedCrossRefGoogle Scholar
  10. Schindler R: Ciclosporin in Autoimmune Diseases. Berlin, Heidelberg, New York, Tokyo: Springer, 1985CrossRefGoogle Scholar
  11. Taube DH, Neild GH, Williams DG, Cameron JS, Hartley B, Ogg CS, Rudge CJ, Welsh KI: Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal-transplant recipients. Lancet II:171, 1985CrossRefGoogle Scholar
  12. Thiel G (ed.): Experimental cyclosporine A nephrotoxicity; An International Workshop, Basle, 1985. Clin Nephrol 25 (Suppl 1):S2-S205, 1986Google Scholar
  13. Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, Van Theil DH: The clearance of cyclosporin by hemodialysis. J Clin Pharmacol 24:528, 1984PubMedGoogle Scholar
  14. Wonigeit K: Pharmakokinetik von Cyclosporin A und Bedeutung der Blutspiegelmessung für die Therapie. Internist 26:534, 1985PubMedGoogle Scholar
  15. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ: Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 40:438, 1986PubMedCrossRefGoogle Scholar

Main references

  1. Hammerl H, Kindler K, Kränzl C, Nebosis G, Pichler O, Studlar M: Über den Einfluß von Cynarin auf Hyperlipidämien unter besonderer Berücksichtigung des Typs II (Hypercholesterinämie). Wien Med Wochenschr 123:601, 1973PubMedGoogle Scholar
  2. Montini M, Levoni P, Ongaro A, Pagani G: Kontrollierte Anwendung von Cynarin in der Behandlung hyperlipämischer Syndrome. Beobachtungen von 60 Fällen. Arzneimittelforsch (Drug Res) 25:1311, 1975Google Scholar

Main references

  1. Berger M, White J, Travis LB, Brouhard BH, Cunningham, III RJ, Patnode R, Petrusick T: Toxic psychosis due to cyproheptadine in a child on hemodialysis: A case report. Clin Nephrol 7:43, 1977PubMedGoogle Scholar
  2. Fischer LJ, Thies RL, Charkowski D, Donham KJ: Formation and urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees, and humans. Drug Metab Dispos 8:422, 1980PubMedGoogle Scholar
  3. Hintze KL, Wold JS, Fischer LJ: Disposition of cyproheptadine in rats, mice, and humans and identification of a stabile epoxide metabolite. Drug Metab Dispos 3:1, 1975PubMedGoogle Scholar
  4. Hucker HB, Balletto AJ, Stauffer SC, Zacchei AG, Arison BH: Physiological disposition and urinary metabolites of cyproheptadine in the dog, rat and cat. Drug Metab Dispos 2:406, 1974PubMedGoogle Scholar
  5. Kennedy KA, Halmi KA, Fischer LJ: Urinary excretion of a quaternary ammonium glucuronide metabolite of cyproheptadine in humans undergoing chronic drug therapy. Life Sci 21:1813, 1977PubMedCrossRefGoogle Scholar
  6. Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJA: Human metabolism of cyproheptadine. Drug Metab Dispos 3:189, 1975PubMedGoogle Scholar
  7. Williams M, Martin GE: Selectivity of cyproheptadine as assessed by radioligand binding. J Pharm Pharmacol 34:58, 1982PubMedCrossRefGoogle Scholar

Main reference

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1395, cyproterone acetateGoogle Scholar

Main references

  1. Chabner B (ed.): Pharmacologic principles of chemotherapy, Philadelphia: WB Saunders, 1982 p 387Google Scholar
  2. Donehower RC, Karp JE, Burke PJ: Pharmacology and toxicity of high-dose Cytarabine by 72-hour continuous infusion. Cancer Treat Rep 70:1059, 1986PubMedGoogle Scholar
  3. Pallavivini MG: Cytosine arabinoside: Molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 25:207, 1984CrossRefGoogle Scholar
  4. Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA: The pharmacokinetics of cytosine arabinoside (ara-C) in the plasma and cerebrospinal fluid (CSF) during conventional and high-dose therapy. Med Pediatr Oncol 10 (Suppl 1): 157, 1982PubMedCrossRefGoogle Scholar
  5. Slevin ML, Johnston A, Woollard RC, Piall EM, Lister TA, Turner P: Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside. J R Soc Med 76:365, 1983PubMedGoogle Scholar
  6. van Prooijen HC, Vierwinden G, Wessels J, Haanen C: Cytosine arabinoside binding to human plasma proteins. Arch Int Pharmacodyn Ther 229:199, 1977Google Scholar
  7. Wan SH, Huffman DH, Azarnoff DL, Hoogstraten B, Larsen WE: Pharmacokinetics of 1-ß-d-arabinofuranosylcytosine in humans. Cancer Res 34:392, 1974PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • Günter Seyffart
    • 1
  1. 1.Dialysis CenterBad HomburgGermany

Personalised recommendations